busulfan and Recrudescence studies

Research Excerpts

Excerpt	Relevance	Reference
"Thiotepa, busulfan and cyclophosphamide-based intensive chemotherapy is an effective treatment for refractory and recurrent primary central nervous system lymphoma in chemosensitive patients up to 65 years of age."	9.16	Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases. ( Bouabdallah, K; Choquet, S; Damaj, G; Delgadillo, D; Dupriez, B; Fourme, E; Ghesquières, H; Gonzalez, A; Hoang-Xuan, K; Houillier, C; Leblond, V; Soussain, C; Taillandier, L; Vargaftig, J, 2012)
"In this prospective study 60 patients of median age 46 (range: 5-60 years), with acute myelogenous leukemia (AML; n = 44), acute lymphoblastic leukemia (ALL; n = 3), or myelodysplastic syndrome (MDS; n = 13) were conditioned for allogeneic hematopoietic cell transplantation with a treosulfan/fludarabine (Flu) combination."	9.15	Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies. ( Appelbaum, FR; Bedalov, A; Deeg, HJ; Doney, KC; Flowers, ME; Guthrie, KA; Hilger, RA; Kovacsovics, TJ; Maziarz, RT; Nemecek, ER; Pagel, JM; Sanders, JE; Scott, BL; Sickle, EJ; Sorror, ML; Witherspoon, R; Wood, BL; Woolfrey, AE, 2011)
" BU, CY and etoposide (BUCYE), followed by auto-SCT (ASCT) in patients with newly diagnosed primary central nervous system lymphoma (PCNSL)."	9.15	Feasibility of BU, CY and etoposide (BUCYE), and auto-SCT in patients with newly diagnosed primary CNS lymphoma: a single-center experience. ( Choi, DR; Huh, J; Kim, S; Kim, SW; Lee, DH; Lee, JS; Lee, SW; Sohn, BS; Suh, C; Yoon, DH, 2011)
"A total of 45 patients with primary myelodysplastic syndromes were conditioned with 3×14 g/m(2) treosulfan and 5×30 mg/m(2) fludarabine followed by allogeneic hematopoietic stem cell transplantation."	9.15	Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial. ( Baumgart, J; Beelen, DW; Blau, IW; Casper, J; Einsele, H; Finke, J; Freund, M; Giebel, S; Gramatzki, M; Holowiecki, J; Kienast, J; Larsson, K; Markiewicz, M; Mylius, HA; Pichlmeier, U; Repp, R; Ruutu, T; Schnitzler, M; Stelljes, M; Stuhler, G; Trenschel, R; Uharek, L; Volin, L; Zander, AR, 2011)
"To evaluate the efficacy of cisplatin, gemcitabine, and treosulfan (CGT) in 91 patients with pretreated relapsed AJCC stage IV cutaneous malignant melanoma."	9.12	Cisplatin, gemcitabine, and treosulfan in relapsed stage IV cutaneous malignant melanoma patients. ( Atzpodien, J; Fluck, M; Reitz, M; Terfloth, K, 2007)
"To reduce the incidence of graft-versus-host disease (GVHD), we added Thymoglobulin (THY) to dose-adjusted oral busulfan plus cyclophosphamide (targeted BUCY)."	9.12	Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. ( Anasetti, C; Appelbaum, FR; Boeckh, M; Deeg, HJ; Doney, KC; Flowers, ME; Hansen, JA; Heimfeld, S; Kiem, HP; Martin, PJ; McCune, JS; Myerson, D; Nash, RA; O'Donnell, PV; Radich, JP; Sandmaier, BM; Scott, BL; Sorror, ML; Storb, R; Storer, BE; Warren, EH; Witherspoon, RP; Woolfrey, A, 2006)
"This phase I/II study evaluated high-dose treosulfan in patients with high-grade lymphoma."	9.11	High-dose treosulfan in patients with relapsed or refractory high-grade lymphoma receiving tandem autologous blood stem cell transplantation. ( Becker, E; Casper, J; Franke, A; Freund, M; Heim, M; Jentsch-Ullrich, K; Koenigsmann, M; Mohren, M, 2004)
"Thirty-four adults with malignant lymphoma at high-risk for relapse were treated on a Phase I-II study of high-dose thiotepa (THIO), busulfan (BU) and cyclophosphamide (CYC) with autologous marrow or peripheral blood stem cell support."	9.08	A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for autologous transplantation for malignant lymphoma. ( Diener, K; Dimopoulos, M; Giralt, S; Hagemeister, F; Ippoliti, C; Khouri, I; Mehra, R; Nath, R; Przepiorka, D; Samuels, B, 1995)
"Between October 1988 and December 1992, 167 patients with leukemia receiving marrow transplants from HLA-identical donors and conditioned with cyclophosphamide (120 mg/kg) were randomized to additional treatment with either busulfan (16 mg/kg, n = 88) or total body irradiation (TBI; n = 79)."	9.07	A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. ( Lenhoff, S; Ljungman, P; Nikoskelainen, J; Parkkali, T; Remberger, M; Ringdén, O; Ruutu, T; Sallerfors, B; Vindeløv, L; Volin, L, 1994)
"Objective The objective of this study was to compare clinical outcomes in children undergoing hematopoietic cell transplantation who received levetiracetam versus those who received phenytoin for the prevention of busulfan-induced seizures."	7.85	Levetiracetam for the prevention of busulfan-induced seizures in pediatric hematopoietic cell transplantation recipients. ( Floeter, AE; McCune, JS, 2017)
"We retrospectively evaluated early and long-term complications of an intensified conditioning regimen consisting of busulfan and etoposide in combination with either nimustine hydrochloride (ACNU) (BVA regimen, n = 18) or melphalan (BVL regimen, n = 34) in 52 children with acute leukemia or non-Hodgkin's lymphoma."	7.74	Long-term follow-up of busulfan, etoposide, and nimustine hydrochloride (ACNU) or melphalan as conditioning regimens for childhood acute leukemia and lymphoma. ( Fujioka, K; Funabiki, T; Goto, H; Goto, S; Hanzawa, N; Ikuta, K; Izaki, S; Kai, S; Matsuda, M; Okuda, K; Sasaki, H; Sekiguchi, H; Sumita, H; Takahashi, H; Watanabe, Y; Yokota, S, 2007)
"We retrospectively compared morbidity and non-relapse mortality (NRM) after allogeneic bone marrow transplantation (BMT) in 236 adults with leukemia and myelodysplastic syndrome conditioned with cyclophosphamide plus oral versus intravenous busulfan."	7.73	Morbidity and non-relapse mortality after allogeneic bone marrow transplantation in adult leukemia patients conditioned with busulfan plus cyclophosphamide: a retrospective comparison of oral versus intravenous busulfan. ( Choi, SJ; Kim, SE; Lee, JH; Lee, KH; Ryu, SG, 2005)
"The present clinical trial was undertaken to investigate the toxicity and antimyeloma activity of busulfan (BU) and cyclophosphamide (CY) at the maximum tolerated doses of, respectively, 16 mg/kg and 200 mg/kg (BU-CY 4) as conditioning therapy for allogeneic bone marrow transplantation (BMT) in 19 consecutive patients with multiple myeloma (MM)."	7.70	High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma. ( Bandini, G; Belardinelli, A; Benni, M; Bonini, A; Cavo, M; Gozzetti, A; Lemoli, RM; Motta, MR; Rizzi, S; Ronconi, S; Rosti, G; Tura, S; Zamagni, E, 1998)
"This study was conducted to evaluate the efficacy of high-dose busulfan (BU) and cyclophosphamide (CY) in patients undergoing autologous hematopoietic stem cell transplantation for metastatic breast cancer."	7.69	High-dose busulfan and cyclophosphamide followed by autologous transplantation in patients with advanced breast cancer. ( Appelbaum, FR; Bensinger, WI; Buckner, CD; Clift, R; Demirer, T; Lilleby, K; Myerson, D; Rowley, S; Storb, R, 1996)
"Preparative regimens containing busulfan (BU) followed by allogeneic bone marrow transplantation (BMT) were used in 27 consecutive patients with myelodysplastic syndromes (MDS)."	7.68	Busulfan-based regimens and allogeneic bone marrow transplantation in patients with myelodysplastic syndromes. ( Cronin, S; Dan, ME; de Planque, MM; Hussein, M; Karanes, C; Lum, LG; Mohamed, A; Ratanatharathorn, V; Schultz, KR; Uberti, J, 1993)
"Busulfan-treated patients had an increased risk of veno-occlusive disease (VOD) of the liver (12% v 1%, P =."	6.69	Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplanta ( Jacobsen, N; Lenhoff, S; Ljungman, P; Mellander, L; Nikoskelainen, J; Parkkali, T; Remberger, M; Ringdén, O; Ruutu, T; Sallerfors, B; Vindeløv, L; Volin, L, 1999)
"All patients are alive with no disease recurrence."	5.40	Busulfan and melphalan as consolidation therapy with autologous peripheral blood stem cell transplantation following Children's Oncology Group (COG) induction platform for high-risk neuroblastoma: early results from a single institution. ( Gross, TG; Pai, V; Ranalli, M; Soni, S, 2014)
" For graft-versus-host disease (GVHD) prophylaxis, cyclosporine and methotrexate were administered."	5.24	Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission. ( Baek, S; Choi, EJ; Choi, Y; Jeon, M; Jo, JC; Joo, YD; Kang, YA; Kang, YL; Kim, DY; Kim, H; Kim, SH; Ko, SH; Lee, JH; Lee, KH; Lee, YS; Lim, SN; Park, HS; Seol, M; Yun, SC, 2017)
" busulfan as myeloablative therapy for autologous HSCT in AML is safe, with mucositis being the most significant toxicity."	5.20	A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia. ( Ai, WZ; Andreadis, C; Benet, LZ; Damon, LE; Gaensler, KM; Kaplan, LD; Koplowicz, YB; Linker, CA; Logan, AC; Mannis, GN; Martin, TG; Olin, RL; Sayre, PH; Smith, CC; Sudhindra, A; Venstrom, JM; Wolf, JL, 2015)
"Thiotepa, busulfan and cyclophosphamide-based intensive chemotherapy is an effective treatment for refractory and recurrent primary central nervous system lymphoma in chemosensitive patients up to 65 years of age."	5.16	Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases. ( Bouabdallah, K; Choquet, S; Damaj, G; Delgadillo, D; Dupriez, B; Fourme, E; Ghesquières, H; Gonzalez, A; Hoang-Xuan, K; Houillier, C; Leblond, V; Soussain, C; Taillandier, L; Vargaftig, J, 2012)
"Sixteen patients diagnosed with various hematologic malignancies participated in a phase II study evaluating the addition of rabbit antithymocyte globulin (rATG, Thymoglobulin(®)) to the hematopoietic cell transplant (HCT) conditioning regimen of IV fludarabine monophosphate (fludarabine) and targeted intravenous (IV) busulfan (fludarabine/(T)busulfan)."	5.16	A pilot pharmacologic biomarker study of busulfan and fludarabine in hematopoietic cell transplant recipients. ( Deeg, HJ; Furlong, T; Heimfeld, S; McCune, JS; O'Donnell, PV; Storer, B; Wang, J; Woodahl, EL, 2012)
" BU, CY and etoposide (BUCYE), followed by auto-SCT (ASCT) in patients with newly diagnosed primary central nervous system lymphoma (PCNSL)."	5.15	Feasibility of BU, CY and etoposide (BUCYE), and auto-SCT in patients with newly diagnosed primary CNS lymphoma: a single-center experience. ( Choi, DR; Huh, J; Kim, S; Kim, SW; Lee, DH; Lee, JS; Lee, SW; Sohn, BS; Suh, C; Yoon, DH, 2011)
"In this prospective study 60 patients of median age 46 (range: 5-60 years), with acute myelogenous leukemia (AML; n = 44), acute lymphoblastic leukemia (ALL; n = 3), or myelodysplastic syndrome (MDS; n = 13) were conditioned for allogeneic hematopoietic cell transplantation with a treosulfan/fludarabine (Flu) combination."	5.15	Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies. ( Appelbaum, FR; Bedalov, A; Deeg, HJ; Doney, KC; Flowers, ME; Guthrie, KA; Hilger, RA; Kovacsovics, TJ; Maziarz, RT; Nemecek, ER; Pagel, JM; Sanders, JE; Scott, BL; Sickle, EJ; Sorror, ML; Witherspoon, R; Wood, BL; Woolfrey, AE, 2011)
"A total of 45 patients with primary myelodysplastic syndromes were conditioned with 3×14 g/m(2) treosulfan and 5×30 mg/m(2) fludarabine followed by allogeneic hematopoietic stem cell transplantation."	5.15	Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial. ( Baumgart, J; Beelen, DW; Blau, IW; Casper, J; Einsele, H; Finke, J; Freund, M; Giebel, S; Gramatzki, M; Holowiecki, J; Kienast, J; Larsson, K; Markiewicz, M; Mylius, HA; Pichlmeier, U; Repp, R; Ruutu, T; Schnitzler, M; Stelljes, M; Stuhler, G; Trenschel, R; Uharek, L; Volin, L; Zander, AR, 2011)
"From 2002 to 2007, 103 patients with primary myelofibrosis or postessential thrombocythemia and polycythemia vera myelofibrosis and a median age of 55 years (range, 32-68 years) were included in a prospective multicenter phase 2 trial to determine efficacy of a busulfan (10 mg/kg)/fludarabine (180 mg/m(2))-based reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation from related (n = 33) or unrelated donors (n = 70)."	5.14	Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. ( Baurmann, H; Bethge, W; Bornhäuser, M; Brand, R; Burchert, A; Corradini, P; de Witte, TM; Dreger, P; Einsele, H; Holler, E; Kaufmann, M; Kobbe, G; Kröger, N; Kvasnicka, HM; Nagler, A; Niederwieser, D; Schubert, J; Schwerdtfeger, R; Stelljes, M; Thiele, J; Uharek, L; Wandt, H; Wulf, GG; Zabelina, T; Zander, AR, 2009)
"We report long-term results after a median follow-up of 105 months in 18 patients with multiple myeloma who received an intensified myeloablative conditioning regimen regimen consisting of modified total body irradiation, busulfan, cyclophosphamide, and antithymocyte globulin, followed by allogeneic stem cell transplantation (SCT)."	5.14	Long-term follow-up of an intensified myeloablative conditioning regimen with in vivo T cell depletion followed by allografting in patients with advanced multiple myeloma. ( Derigs, G; Einsele, H; Kröger, N; Krüll, A; Wandt, H; Zander, A, 2010)
"To reduce the incidence of graft-versus-host disease (GVHD), we added Thymoglobulin (THY) to dose-adjusted oral busulfan plus cyclophosphamide (targeted BUCY)."	5.12	Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. ( Anasetti, C; Appelbaum, FR; Boeckh, M; Deeg, HJ; Doney, KC; Flowers, ME; Hansen, JA; Heimfeld, S; Kiem, HP; Martin, PJ; McCune, JS; Myerson, D; Nash, RA; O'Donnell, PV; Radich, JP; Sandmaier, BM; Scott, BL; Sorror, ML; Storb, R; Storer, BE; Warren, EH; Witherspoon, RP; Woolfrey, A, 2006)
" Using conditioning consisting of fludarabine, busulfan, and anti-T-lymphocyte globulin and GVHD prophylaxis consisting of tacrolimus and methylprednisolone (1 mg/kg/day), 26 patients who had hematologic malignancies in an advanced stage or with a poor prognosis underwent transplantation using peripheral blood stem cells from an HLA-haploidentical donor (2-3 antigen mismatches in the graft-versus-host [GVH] direction) without T-cell depletion."	5.12	Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning. ( Fujioka, T; Hasei, H; Ikegame, K; Inoue, T; Kaida, K; Kawakami, M; Kawase, I; Kim, EH; Masuda, T; Ogawa, H; Taniguchi, Y; Yoshihara, S, 2006)
"To evaluate the efficacy of cisplatin, gemcitabine, and treosulfan (CGT) in 91 patients with pretreated relapsed AJCC stage IV cutaneous malignant melanoma."	5.12	Cisplatin, gemcitabine, and treosulfan in relapsed stage IV cutaneous malignant melanoma patients. ( Atzpodien, J; Fluck, M; Reitz, M; Terfloth, K, 2007)
"This phase I/II study evaluated high-dose treosulfan in patients with high-grade lymphoma."	5.11	High-dose treosulfan in patients with relapsed or refractory high-grade lymphoma receiving tandem autologous blood stem cell transplantation. ( Becker, E; Casper, J; Franke, A; Freund, M; Heim, M; Jentsch-Ullrich, K; Koenigsmann, M; Mohren, M, 2004)
"Autologous stem cell transplantation after high-dose melphalan for the treatment with multiple myeloma has resulted in prolonged progression-free survival and overall survival in patients under 65 years."	5.09	The role of autologous transplantation in patients with multiple myeloma aged 65 years and over. ( Bhagwati, N; Horton, C; Kulkarni, S; Mainwaring, P; Mehta, J; Pandha, H; Powles, R; Singhal, S; Sirohi, B; Treleaven, J, 2000)
"Thirty-four adults with malignant lymphoma at high-risk for relapse were treated on a Phase I-II study of high-dose thiotepa (THIO), busulfan (BU) and cyclophosphamide (CYC) with autologous marrow or peripheral blood stem cell support."	5.08	A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for autologous transplantation for malignant lymphoma. ( Diener, K; Dimopoulos, M; Giralt, S; Hagemeister, F; Ippoliti, C; Khouri, I; Mehra, R; Nath, R; Przepiorka, D; Samuels, B, 1995)
"Between October 1988 and December 1992, 167 patients with leukemia receiving marrow transplants from HLA-identical donors and conditioned with cyclophosphamide (120 mg/kg) were randomized to additional treatment with either busulfan (16 mg/kg, n = 88) or total body irradiation (TBI; n = 79)."	5.07	A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group. ( Lenhoff, S; Ljungman, P; Nikoskelainen, J; Parkkali, T; Remberger, M; Ringdén, O; Ruutu, T; Sallerfors, B; Vindeløv, L; Volin, L, 1994)
" We aimed to identify the risk factors that predict transplantation outcomes in patients with MF who underwent matched or mismatched allo-SCT using a uniform myeloablative conditioning regimen consisting of busulfan and fludarabine with tacrolimus and methotrexate-based graft-versus-host disease prophylaxis."	4.31	Transplantation Outcomes of Myelofibrosis with Busulfan and Fludarabine Myeloablative Conditioning. ( Alousi, AM; Bashir, Q; Champlin, RE; Hosing, C; Joseph, J; Kebriaei, P; Milton, DR; Olson, AL; Oran, B; Popat, UR; Qazilbash, MH; Ramdial, JL; Saini, NY; Shpall, EJ; Srour, SA, 2023)
"Myeloablative conditioning regimens decrease the risk of relapse in pediatric patients undergoing allogeneic hematopoietic stem cell transplant (HCT) for hematologic malignancies, but cause significant toxicities PROCEDURE: This prospective study evaluated the use of a reduced-toxicity, myeloablative regimen with dose-adjusted busulfan, fludarabine, antithymocyte globulin and 400 cGy of total body irradiation in 40 patients < 21 years of age undergoing HCT for high-risk leukemias."	4.02	Reduced-toxicity conditioning regimen with busulfan, fludarabine, rATG, and 400 cGy TBI in pediatric patients undergoing hematopoietic stem cell transplant for high-risk hematologic malignancies. ( Chaudhury, S; Duerst, RE; Jacobsohn, D; Kletzel, M; Kwon, S; Rossoff, J; Schneiderman, J; Tse, WT, 2021)
"Objective The objective of this study was to compare clinical outcomes in children undergoing hematopoietic cell transplantation who received levetiracetam versus those who received phenytoin for the prevention of busulfan-induced seizures."	3.85	Levetiracetam for the prevention of busulfan-induced seizures in pediatric hematopoietic cell transplantation recipients. ( Floeter, AE; McCune, JS, 2017)
"Haploidentical hematopoietic cell transplantation (HCT) conditioning with clofarabine and target area under the blood concentration-time curve (AUC)-based busulfan adjustment was performed in three patients with refractory pediatric leukemia."	3.85	HLA haploidentical hematopoietic cell transplantation using clofarabine and busulfan for refractory pediatric hematological malignancy. ( Aoki, Y; Fujimura, J; Hoshino, A; Imai, K; Ishiwata, Y; Kajiwara, M; Kanegane, H; Mae, T; Matsumoto, K; Mitsuiki, N; Miyamoto, S; Mizutani, S; Morio, T; Nishimura, A; Takagi, M; Takikawa, K; Tanaka, M; Tomita, O; Tomizawa, D; Yanagimachi, M; Yasuhara, M, 2017)
"To investigate the safety and efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for myelodysplastic syndrome (MDS) and secondary acute myelogenous leukemia (MDS-AML) using conditioning regimen with busulfan (Bu) and increased-dose of fludarabine (ID-Flu)."	3.81	[Combination of busulfan with increased-dose of fludarabine as conditioning regimen for MDS and MDS-AML patients with allo-HSCT]. ( Cen, X; Dong, Y; Li, Y; Liang, Z; Liu, W; Ou, J; Qiu, Z; Ren, H; Sun, Y; Wang, L; Wang, M; Wang, Q; Wang, W; Xu, W; Yin, Y; Yuan, J, 2015)
"We retrospectively evaluated early and long-term complications of an intensified conditioning regimen consisting of busulfan and etoposide in combination with either nimustine hydrochloride (ACNU) (BVA regimen, n = 18) or melphalan (BVL regimen, n = 34) in 52 children with acute leukemia or non-Hodgkin's lymphoma."	3.74	Long-term follow-up of busulfan, etoposide, and nimustine hydrochloride (ACNU) or melphalan as conditioning regimens for childhood acute leukemia and lymphoma. ( Fujioka, K; Funabiki, T; Goto, H; Goto, S; Hanzawa, N; Ikuta, K; Izaki, S; Kai, S; Matsuda, M; Okuda, K; Sasaki, H; Sekiguchi, H; Sumita, H; Takahashi, H; Watanabe, Y; Yokota, S, 2007)
"We have reported a lower incidence of acute graft-versus-host disease (aGVHD) with a novel conditioning regimen using low-dose rabbit antithymocyte globulin (ATG; Thymoglobulin [TG]) with fludarabine and intravenous busulfan (FluBuTG)."	3.74	Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide. ( Agovi, MA; Bacigalupo, A; Bahlis, NJ; Ballen, K; Bredeson, CN; Brown, C; Chaudhry, MA; Horowitz, MM; Kurian, S; Muehlenbien, CE; Quinlan, D; Rizzo, JD; Russell, JA; Savoie, L; Stewart, DA; Zhang, MJ, 2008)
"We retrospectively compared morbidity and non-relapse mortality (NRM) after allogeneic bone marrow transplantation (BMT) in 236 adults with leukemia and myelodysplastic syndrome conditioned with cyclophosphamide plus oral versus intravenous busulfan."	3.73	Morbidity and non-relapse mortality after allogeneic bone marrow transplantation in adult leukemia patients conditioned with busulfan plus cyclophosphamide: a retrospective comparison of oral versus intravenous busulfan. ( Choi, SJ; Kim, SE; Lee, JH; Lee, KH; Ryu, SG, 2005)
" In this report, we analyzed the outcome of 101 high-risk patients (70 hematologic and 31 nonhematologic malignancies) who received an HLA-identical sibling allo-SCT after RIC, including fludarabine, busulfan, and antithymocyte globulin (ATG)."	3.72	Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. ( Bay, JO; Bilger, K; Blaise, D; Chabannon, C; Choufi, B; Coso, D; Faucher, C; Maraninchi, D; Mohty, M; Stoppa, AM; Tournilhac, O; Vey, N; Viens, P, 2003)
"Using nonmyeloablative, immunosuppressive, fludarabine (FLU)-based conditioning regimens, we have performed allogeneic peripheral blood stem cell transplants in 26 patients (8 with chronic myelogenous leukemia, 6 with acute myelogenous leukemia, 10 with acute lymphoblastic leukemia, 1 with myelodysplasia, and 1 with thalassemia major)."	3.71	Results of an outpatient-based stem cell allotransplant program using nonmyeloablative conditioning regimens. ( Cantú, OG; Gómez-Almaguer, D; González-Llano, O; Jaime-Pérez, JC; Ruiz-Argüelles, A; Ruiz-Argüelles, GJ, 2001)
" Graft-versus-host disease prophylaxis consisted of cyclosporine and a short course of methotrexate."	3.71	A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome. ( Kabisch, H; Kröger, N; Krüger, W; Renges, H; Schetelig, J; Schrum, J; Siegert, W; Stute, N; Zabelina, T; Zander, AR, 2001)
"The present clinical trial was undertaken to investigate the toxicity and antimyeloma activity of busulfan (BU) and cyclophosphamide (CY) at the maximum tolerated doses of, respectively, 16 mg/kg and 200 mg/kg (BU-CY 4) as conditioning therapy for allogeneic bone marrow transplantation (BMT) in 19 consecutive patients with multiple myeloma (MM)."	3.70	High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma. ( Bandini, G; Belardinelli, A; Benni, M; Bonini, A; Cavo, M; Gozzetti, A; Lemoli, RM; Motta, MR; Rizzi, S; Ronconi, S; Rosti, G; Tura, S; Zamagni, E, 1998)
" Graft-versus-host disease (GVHD) prophylaxis was attempted with cyclosporine A (CYA) and methotrexate."	3.70	[Severe hepatic veno-occlusive disease (VOD) which was successfully treated with supportive therapy, but subsequently developed late-recurrence]. ( Hirabayashi, N; Ikeda, Y; Ishida, A; Matsuoka, S; Moriki, T; Okamoto, S; Wakui, M; Watanabe, R, 1998)
"This study was conducted to evaluate the efficacy of high-dose busulfan (BU) and cyclophosphamide (CY) in patients undergoing autologous hematopoietic stem cell transplantation for metastatic breast cancer."	3.69	High-dose busulfan and cyclophosphamide followed by autologous transplantation in patients with advanced breast cancer. ( Appelbaum, FR; Bensinger, WI; Buckner, CD; Clift, R; Demirer, T; Lilleby, K; Myerson, D; Rowley, S; Storb, R, 1996)
"Preparative regimens containing busulfan (BU) followed by allogeneic bone marrow transplantation (BMT) were used in 27 consecutive patients with myelodysplastic syndromes (MDS)."	3.68	Busulfan-based regimens and allogeneic bone marrow transplantation in patients with myelodysplastic syndromes. ( Cronin, S; Dan, ME; de Planque, MM; Hussein, M; Karanes, C; Lum, LG; Mohamed, A; Ratanatharathorn, V; Schultz, KR; Uberti, J, 1993)
"Strategies to reduce recurrence are urgently required."	3.01	Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia. ( Andrew, G; Byrne, J; Craddock, C; Crawley, C; Dillon, R; Freeman, SD; Gilleece, M; Hodgkinson, A; Hunter, A; Jackson, A; Khan, N; Loke, J; Malladi, R; Mason, J; McCarthy, N; Nagra, S; Parker, A; Pavlu, J; Peniket, A; Potter, V; Protheroe, R; Salim, R; Siddique, S; Tholouli, E; Vyas, P; Wheatley, K; Wilson, K, 2021)
"Fifty-four patients with advanced hematologic malignancies were enrolled on this study."	2.80	Phase I/II Trial of Dose-Escalated Busulfan Delivered by Prolonged Continuous Infusion in Allogeneic Transplant Patients. ( Armistead, P; Chung, Y; Coghill, J; Comeau, T; Gabriel, D; Ivanova, A; Rao, K; Sarantopoulos, S; Serody, J; Shea, TC; Sheets, J; Walko, C; Wood, W, 2015)
"Vorinostat was given at 200 mg/day to 1000 mg/day (days -8 to -3)."	2.80	Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. ( Ahmed, S; Alousi, A; Anderlini, P; Andersson, BS; Bashir, Q; Champlin, R; Dabaja, B; Fanale, M; Gulbis, A; Hagemeister, F; Hosing, C; Jones, RB; Liu, Y; Nieto, Y; Oki, Y; Pinnix, C; Popat, U; Qazilbash, M; Shah, N; Shpall, EJ; Thall, PF; Valdez, BC, 2015)
"Comparing patients with acute myeloid leukemia/myelodysplastic syndrome versus those with acute lymphoblastic leukemia/bi-phenotypic leukemia, the 1-year overall and leukemia-free survival rates were 75±10% versus 50±13%, respectively (P=0."	2.79	Results from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trial. ( Bilger, K; Blaise, D; Chevallier, P; de La Tour, RP; Delaunay, J; El-Cheikh, J; Furst, S; Guillaume, T; Labopin, M; Lioure, B; Michallet, M; Milpied, N; Mohty, M; Moreau, P; Socié, G; Tabrizi, R; Vigouroux, S, 2014)
"In AML patients, minimal residual disease (MRD; n = 10) at the time of HCT predicted higher relapse incidence (70% versus 18%) and lower OS (41% versus 79%) at 2 years, when compared with patients without MRD."	2.79	Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia. ( Appelbaum, FR; Bar, M; Baumgart, J; Deeg, HJ; Delaney, C; Estey, EH; Fang, M; Gutman, J; Gyurkocza, B; Maziarz, RT; Milano, F; Nemecek, ER; Pagel, JM; Ramakrishnan, A; Sandmaier, BM; Scott, B; Storer, BE; Wood, B, 2014)
"Stomatitis was the most frequent toxicity in both trials."	2.78	Dose escalation of total marrow irradiation with concurrent chemotherapy in patients with advanced acute leukemia undergoing allogeneic hematopoietic cell transplantation. ( Forman, S; Liu, A; Palmer, J; Radany, E; Rosenthal, J; Schultheiss, T; Somlo, G; Stein, A; Wong, JY, 2013)
" Our data suggest that a phase II trial should incorporate CPX-351 120 U/m(2) × 3 dosing on schedule B."	2.78	A phase I study of CPX-351 in combination with busulfan and fludarabine conditioning and allogeneic stem cell transplantation in adult patients with refractory acute leukemia. ( Christos, P; Feldman, E; Gergis, U; Mark, T; Mayer, S; McKenna, M; Pearse, R; Ritchie, E; Roboz, G; Scandura, J; Shore, T; van Besien, K; Wissa, U, 2013)
"busulfan doses 1 and 2 were 170 mg/m(2)/day, then doses 3 and 4 were adjusted based on first-dose pharmacokinetic modeling to achieve an average daily AUC of 6,000 μM-min."	2.77	Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation. ( Anasetti, C; Ayala, E; Fernandez, HF; Field, TL; Kharfan-Dabaja, MA; Kim, J; Perez, LE; Perkins, JB; Pidala, JA; Sullivan, DM; Tomblyn, MR, 2012)
"or i."	2.77	A prospective multicenter study of treosulfan in elderly patients with recurrent ovarian cancer: results of a planned safety analysis. ( Belau, A; Fuxius, S; Heidrich-Lorsbach, E; Heuser, T; Klare, P; Kölbl, H; Mahner, S; Markmann, S; Oskay-Özcelik, G; Ruhmland, B; Sehouli, J; Sommer, H, 2012)
"Busulfan (1."	2.77	Phase II study of dose-modified busulfan by real-time targeting in allogeneic hematopoietic stem cell transplantation for myeloid malignancy. ( Atsuta, Y; Fukumoto, M; Inamoto, Y; Karasuno, T; Kohno, A; Kuwatsuka, Y; Miyamura, K; Morishita, Y; Murata, M; Nagafuji, K; Naoe, T; Saito, S; Sawa, M; Shimada, K; Suzuki, R; Taniguchi, S; Terakura, S; Yasuda, T, 2012)
"For patients with relapsed or refractory multiple myeloma (MM) treated with a prior high-dose therapy (HDT) followed by autologous peripheral blood stem cell transplantation (PBSCT), the reapplication of HDT is a widely used salvage strategy."	2.76	Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation. ( Balleisen, S; Bruns, I; Fenk, R; Haas, R; Kobbe, G; Kondakci, M; Liese, V; Neubauer, F; Saure, C; Schröder, T, 2011)
"Relapses were similar in both arms."	2.71	Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: a Pediatric Blood and Marrow Transplant Consortium study. ( Aplenc, R; Bunin, N; Cnaan, A; Kamani, N; Shaw, K; Simms, S, 2003)
" Dose-escalated treosulphan (3 x 12 or 3 x 14 g/m2) combined with cyclophosphamide (Cy) was chosen for a new preparative regimen before allogeneic haematopoietic stem cell transplantation in 18 patients (median age 44, range 19-64 years) with haematological malignancies, considered ineligible for other myeloablative preparative regimens."	2.71	Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications. ( Basara, N; Baumgart, J; Beelen, DW; Casper, J; Fauser, AA; Freund, M; Hahn, JR; Hertenstein, B; Hilger, RA; Holler, E; Mylius, HA; Pichlmeier, U; Scheulen, ME; Trenschel, R, 2005)
" Reduced-intensity allogeneic SCT may offer a less toxic approach to patients with AML."	2.71	Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia. ( Bhatia, M; Bradley, B; Cairo, MS; Cooney, E; Del Toro, G; Foley, S; Garvin, J; George, D; Harrison, L; Hawks, R; Militano, O; Roman, E; Satwani, P; Unal, E; van de Ven, C; Wolownik, K, 2005)
"The CI of relapse was 25% at 3 years."	2.70	Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality. ( Anasetti, C; Anderson, JE; Appelbaum, FR; Bryant, E; Chauncey, T; Deeg, HJ; Doney, K; Flowers, ME; Hansen, J; Jurado, M; Martin, PJ; Nash, RA; Petersdorf, E; Radich, J; Sale, G; Sandmaier, BM; Storb, R; Storer, B; Wade, J; Witherspoon, R, 2002)
"Ten patients who relapsed are alive a median of 31 months (range, 6-47) after relapse."	2.69	High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin's lymphoma. ( Buckner, CD; Rhinehart, S; Schwartzberg, L; Weaver, CH; West, J; West, WH; Zhen, B, 1998)
"Busulfan-treated patients had an increased risk of veno-occlusive disease (VOD) of the liver (12% v 1%, P =."	2.69	Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplanta ( Jacobsen, N; Lenhoff, S; Ljungman, P; Mellander, L; Nikoskelainen, J; Parkkali, T; Remberger, M; Ringdén, O; Ruutu, T; Sallerfors, B; Vindeløv, L; Volin, L, 1999)
"Leukemic recurrence was observed in eight patients."	2.68	Allogeneic bone marrow transplantation following a busulfan-based conditioning regimen in young children with acute lymphoblastic leukemia: a Cooperative Study of the Société Française de Greffe de Moelle. ( Bernaudin, F; Cornu, G; Demeocq, F; Donadieu, J; Esperou-Bourdeau, H; Mechinaud-Lacroix, F; Michel, G; Sadoun, A; Souillet, G; von Bueltzingsloewen, A, 1995)
"Current intensive chemotherapy for acute nonlymphoblastic leukemia (ANLL) results in a complete remission in the majority of patients."	2.67	Busulfan/etoposide--initial experience with a new preparatory regimen for autologous bone marrow transplantation in patients with acute nonlymphoblastic leukemia. ( Amylon, MD; Blume, KG; Chao, NJ; Forman, SJ; Long, GD; Negrin, RS; Stein, AS; Wong, RM, 1993)
"One hundred fifteen patients with chronic myelocytic leukemia (CML) were administered busulphan 4 mg/kg for 4 days and cyclophosphamide 60 mg/kg on each of 2 days (BuCy2) followed by allogeneic bone marrow transplantation from histocompatible sibling donors."	2.67	Treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation after preparation with BuCy2. ( Atkinson, K; Avalos, B; Biggs, JC; Concannon, AJ; Crilley, P; Dodds, A; Downs, K; Kapoor, N; Szer, J; Tutschka, P, 1992)
"One hundred twenty-seven patients with acute myelocytic leukemia (AML) were given busulfan 4 mg/kg on each of 4 days and cyclophosphamide 60 mg/kg on each of 2 days (BuCy2) followed by allogeneic bone marrow transplantation from an HLA-identical or one antigen disparate sibling."	2.67	Treatment for acute myelocytic leukemia with allogeneic bone marrow transplantation following preparation with BuCy2. ( Atkinson, K; Avalos, BR; Biggs, JC; Copelan, EA; Crilley, P; Cunningham, I; Kapoor, N; Klein, JP; Szer, J; Thompson, JM, 1991)
"Relapse is one of the main complications."	2.38	Influence of various conditioning regimens on the outcome of bone marrow transplantation for leukemia. ( Devergie, A; Esperou-Bourdeau, H; Gluckman, E; Ribaud, P; Socie, G; Traineau, R, 1991)
"In conclusion, ATG and PTCy combined with Flu-based increased intensity conditioning regimen is effective for acute leukemia in children."	1.91	Intensified conditioning regimen with fludarabine combined with post-transplantation cyclophosphamide for haploidentical allogeneic hematopoietic stem cell transplantation in children with high-risk acute leukemia. ( Cao, J; Chen, D; Li, S; Liu, X; Lu, Y; Pei, R; Wang, T; Xu, X; Ye, P; Zheng, ZZ, 2023)
" The prediction of transplantation-related mortality (TRM) using the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) score and an arbitrary upper age limit of 55 years for administering myeloablative conditioning (MAC) are common strategies to ensure a safe procedure."	1.91	Myeloablative Dose of Busulfan and Fludarabine Combined with In Vivo T Cell Depletion Is Safe and Effective Conditioning for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients. ( Alshehri, H; Anteh, S; Avenoso, D; Bourlon, C; Bouziana, S; Dazzi, F; de Farias, M; Dragoi, OD; Gameil, A; Hannah, G; Kenyon, M; Krishnamurthy, P; Kulasekararaj, A; Leung, YT; Mehra, V; Pagliuca, A; Potter, V; Serpenti, F; Shah, MN; Slonim, LB; Wood, H, 2023)
"Total body irradiation (TBI) at a dose of 12 Gy combined with cyclophosphamide (CyTBI12Gy) is one of the standard myeloablative regimens for patients with acute myeloid leukemia (AML) treated with allogeneic hematopoietic cell transplantation (allo-HCT)."	1.91	Fludarabine versus cyclophospamide in combination with myeloablative total body irradiation as conditioning for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study from the Acute Leukemia Working Party ( Arat, M; Bourhis, JH; Cornelissen, JJ; Giebel, S; Grillo, G; Hilgendorf, I; Kröger, N; Labopin, M; Maertens, J; Mohty, M; Nagler, A; Poiré, X; Salmenniemi, U; Savani, B; Schroeder, T; Spyridonidis, A; Swoboda, R, 2023)
" Here, we compared post-transplant outcomes after individualized versus fixed busulfan dosage in intermediate-risk AML who achieved CR prior to allograft focusing on pre-transplant flow-MRD."	1.91	Individualized busulfan dosing improves outcomes compared to fixed-dose administration in pre-transplant minimal residual disease-positive acute myeloid leukemia patients with intermediate-risk undergoing allogeneic stem cell transplantation in CR. ( Ayuk, F; Bacher, U; Badbaran, A; Dadkhah, A; Freiberger, P; Janson, D; Klyuchnikov, E; Kröger, N; Langebrake, C; Massoud, R; Wolschke, C, 2023)
"Optimal conditioning for adults with acute lymphoblastic leukemia (ALL) treated with haploidentical hematopoietic cell transplantation (haplo-HCT) and post-transplant cyclophosphamide has not been established so far."	1.72	Total body irradiation plus fludarabine versus thiotepa, busulfan plus fludarabine as a myeloablative conditioning for adults with acute lymphoblastic leukemia treated with haploidentical hematopoietic cell transplantation. A study by the Acute Leukemia W ( Aljurf, M; Angelucci, E; Arat, M; Bernasconi, P; Giebel, S; Labopin, M; Mohty, M; Nagler, A; Pavlu, J; Peric, Z; Pioltelli, P; Rigacci, L; Risitano, A; Rovira, M; Saccardi, R; Savani, BN; Sica, S; Socié, G; Spyridonidis, A; Swoboda, R; Tischer, J; Van Gorkom, G; Vitek, A, 2022)
" In 2019, we changed Bu dosing from 4×/day (Bu-4) to 1×/day (Bu-1) for ease of application."	1.72	Impact of busulfan pharmacokinetics on outcome in adult patients receiving an allogeneic hematopoietic cell transplantation. ( Battegay, R; Halter, J; Heim, D; Medinger, M; Passweg, JR; Rentsch, KM; Seydoux, C, 2022)
"We prospectively studied clofarabine-fludarabine-busulfan (CloFluBu)-conditioning in allogeneic hematopoietic cell therapy (HCT) for lymphoid and myeloid malignancies and hypothesized that CloFluBu provides a less toxic alternative to conventional conditioning regimens, with adequate antileukemic activity."	1.72	Clofarabine-fludarabine-busulfan in HCT for pediatric leukemia: an effective, low toxicity, TBI-free conditioning regimen. ( Bierings, M; Boelens, JJ; Bresters, D; de Koning, CCH; Kollen, WJ; Lankester, AC; Lindemans, CA; Nierkens, S; Versluijs, AB, 2022)
" Pharmacokinetic dosing of busulfan (Bu) is frequently done for myeloablative conditioning, but evidence for its use is limited in RIC transplants."	1.43	Fludarabine-Busulfan Reduced-Intensity Conditioning in Comparison with Fludarabine-Melphalan Is Associated with Increased Relapse Risk In Spite of Pharmacokinetic Dosing. ( Al-Kali, A; Alkhateeb, HB; Damlaj, M; Gangat, N; Gastineau, DA; Hashmi, S; Hefazi, M; Hogan, WJ; Litzow, MR; Partain, DK; Patnaik, MM; Wolf, RC, 2016)
"However, the effect of Gilbert's syndrome on the disposition of some drugs can lead to unexpected toxicity."	1.43	Mortality outcomes after busulfan-containing conditioning treatment and haemopoietic cell transplantation in patients with Gilbert's syndrome: a retrospective cohort study. ( Evans, AT; Gooley, TA; McCune, JS; McDonald, GB; Ostrow, JD; Schoch, G, 2016)
"Pediatric patients with acute myeloid leukemia (AML) mainly receive myeloablative conditioning regimens based on busulfan (BU) or total body irradiation (TBI) before allogeneic hematopoietic cell transplantation (allo-HCT); however, the optimal conditioning regimen remains unclear."	1.42	Comparison of Outcomes for Pediatric Patients With Acute Myeloid Leukemia in Remission and Undergoing Allogeneic Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens Based on Either Intravenous Busulfan or Total Body Irradiation: A ( Adachi, S; Atsuta, Y; Goto, H; Inagaki, J; Inoue, M; Ishida, H; Kato, K; Kato, M; Kawano, Y; Koh, K; Kudo, K; Miyamura, T; Ogawa, A; Sawada, A; Taga, T; Terui, K; Tomizawa, D; Yamashita, T, 2015)
" We aimed this retrospective study for comparison of weight- and age-based dosing in terms of clinical outcomes such as time to engraftment, early complications, EFS, OS, and toxicity profiles in children receiving iv Bu."	1.42	Clinical comparison of weight- and age-based strategy of dose administration in children receiving intravenous busulfan for hematopoietic stem cell transplantation. ( Avci, Z; Azik, F; Gürlek Gökçebay, D; Isik, P; Kara, A; Ozbek, N; Tavil, B; Tunc, B, 2015)
" Pharmacokinetic treatment with targeted intravenous busulfan combined with fludarabine (BuFlu) was developed as a preparative regimen for acute leukemia and myelodysplasia."	1.42	Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma. ( Anasetti, C; Ayala, E; Figueroa, J; Kharfan-Dabaja, MA; Kim, J; Locke, F; Nishihori, T; Perkins, J; Riches, M; Yue, B, 2015)
"All patients are alive with no disease recurrence."	1.40	Busulfan and melphalan as consolidation therapy with autologous peripheral blood stem cell transplantation following Children's Oncology Group (COG) induction platform for high-risk neuroblastoma: early results from a single institution. ( Gross, TG; Pai, V; Ranalli, M; Soni, S, 2014)
"Lower dosage of total body irradiation (TBI) and chemotherapy in reduced-intensity conditioning (RIC) regimens prior to allogeneic stem cell transplantation have reduced the toxicity of the conditioning and non-relapse mortality."	1.38	Intermediate intensity conditioning regimen containing FLAMSA, treosulfan, cyclophosphamide, and ATG for allogeneic stem cell transplantation in elderly patients with relapsed or high-risk acute myeloid leukemia. ( Brossart, P; Chemnitz, JM; Hallek, M; Holtick, U; Krause, A; Scheid, C; Shimabukuro-Vornhagen, A; Theurich, S; von Lilienfeld-Toal, M, 2012)
"Gemcitabine dose was escalated by extending infusions at a fixed rate of 10 mg/m(2)/min in sequential cohorts, in daily, 3-dose or 2-dose schedules."	1.38	High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies. ( Alousi, A; Anderlini, P; Andersson, B; Bashir, Q; Bassett, R; Champlin, R; Chancoco, C; Ciurea, S; Frazier, E; Gulbis, A; Hosing, C; Jones, RB; Kebriaei, P; Khouri, I; Nieto, Y; Parmar, S; Popat, U; Qazilbash, M; Rondon, G; Shah, N; Shpall, EJ; Thall, P; Valdez, B; Worth, L, 2012)
"We used pharmacokinetic (PK) targeting of BU in 145 consecutive patients treated with fludarabine and i."	1.37	Pharmacokinetic targeting of i.v. BU with fludarabine as conditioning before hematopoietic cell transplant: the effect of first-dose area under the concentration time curve on transplant-related outcomes. ( Anasetti, C; Ayala, E; Fancher, K; Fernandez, H; Field, T; Gardiner, JA; Kharfan-Dabaja, MA; Kim, J; Miller, S; Milone, MC; Perez, L; Perkins, J; Shaw, LM; Tate, C, 2011)
"IV busulfan was associated with a lower rate of relapse, and superior relapse-free survival (RFS) and OS."	1.36	Superior survival after replacing oral with intravenous busulfan in autologous stem cell transplantation for non-Hodgkin lymphoma with busulfan, cyclophosphamide and etoposide. ( Andresen, S; Bolwell, BJ; Copelan, EA; Curtis, J; Dean, RM; Kalaycio, ME; Pohlman, B; Rybicki, LA; Smith, SD; Sobecks, RM; Sweetenham, JW, 2010)
"This study reports on overall and recurrence-free survival (OS and RFS) of 37 consecutive patients with low- and intermediate-grade NHL receiving a related donor allogeneic BMT using a nonradiation-containing preparative regimen."	1.32	Busulfan and cyclophosphamide as a preparative regimen for allogeneic blood and marrow transplantation in patients with non-Hodgkin's lymphoma. ( Kiss, TL; Lipton, JH; Meharchand, J; Messner, HA; Panzarella, T; Reddy, V; Schimmer, AD, 2003)
"Death and treatment failure (relapse or death, inverse of leukemia-free survival) were more frequent in the Bu/CY group (RR, 1."	1.31	Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. ( Bolwell, B; Cahn, JY; Camitta, BM; Davies, SM; Gale, RP; Giralt, S; Heilmann, C; Henslee-Downey, PJ; Herzig, RH; Horowitz, MM; Hutchinson, R; Keating, A; Klein, JP; Lazarus, HM; Milone, GA; Neudorf, S; Perez, WS; Powles, RL; Prentice, HG; Ramsay, NK; Schiller, G; Socié, G; Vowels, M; Weisdorf, DJ; Wiley, J; Yeager, A, 2000)
"To evaluate the efficacy and toxicity of two different etoposide (VP-16) dosages (30 or 45 mg/kg) in combination with busulfan/cyclophosphamide as conditioning therapy followed by stem cell transplantation in acute myeloid leukemia (AML), 90 patients with AML received either 30 mg/kg (n = 60) or 45 mg/kg (n = 30) etoposide in combination with busulfan (16 mg/kg) and cyclophosphamide (120 mg/kg)."	1.31	Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia. ( Braumann, D; Colberg, H; del Valle, F; Erttmann, R; Fiedler, W; Finkenstein, F; Holstein, K; Kabisch, H; Kröger, N; Krüger, W; Kuse, R; Mayer, U; Metzner, B; Renges, H; Sonnen, R; Sonnenberg, S; Stute, N; Zabelina, T; Zander, AR, 2000)
" Plasma concentrations of BU at steady state (C(SS)BU) during the dosing interval were measured for each patient."	1.30	Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. ( Anasetti, C; Appelbaum, FR; Bensinger, WI; Bowden, R; Bryant, E; Buckner, CD; Chauncey, T; Clift, RA; Deeg, HJ; Doney, KC; Flowers, M; Gooley, T; Hansen, JA; Martin, PJ; McDonald, GB; Nash, R; Petersdorf, EW; Radich, J; Sanders, JE; Schoch, G; Slattery, JT; Soll, E; Stewart, P; Storb, R; Storer, B; Sullivan, KM; Thomas, ED; Witherspoon, RP, 1997)
"Fifty patients with acute myeloid leukemia (AML) or chronic myeloid leukemia (CML) underwent allogeneic bone marrow transplantation between October 1988 and January 1997."	1.30	Busulfan, cyclophosphamide and total body irradiation as conditioning for allogeneic bone marrow transplantation for acute and chronic myeloid leukemia. ( Goto, S; Hirabayashi, N; Ishii, M; Mitsuma, A; Noda, N; Yuge, M, 1998)
"BUF rats suffering from severe relapsing experimental autoimmune encephalomyelitis (R-EAE), a model for multiple sclerosis, were treated with intensive cytoreductive therapy and grafting of allogeneic bone marrow (BM)."	1.29	Treatment of relapsing experimental autoimmune encephalomyelitis with largely MHC-matched allogeneic bone marrow transplantation. ( Mulder, AH; van Bekkum, DW; van Gelder, M, 1996)
"Clonal chromosome aberrations observed in patients who have relapsed after autologous bone marrow transplantation (ABMT) are usually related to the cytogenetic abnormalities observed at diagnosis."	1.29	Detection of occasional and clonal chromosome aberrations in patients with acute non-lymphocytic leukemia after autologous bone marrow transplantation. ( Gherlinzoni, F; Manfroi, S; Mangianti, S; Martinelli, G; Miggiano, MC; Pelliconi, S; Testoni, N; Tura, S; Visani, G; Zaccaria, A, 1996)
" There were seven acute toxic deaths (8%) and in total 15 patients experienced life-threatening or fatal toxicity."	1.29	Extramedullary toxicity of a conditioning regimen containing busulphan, cyclophosphamide and etoposide in 84 patients undergoing autologous and allogenic bone marrow transplantation. ( Bernstein, E; Brodsky, I; Bulova, S; Crilley, P; Marks, DI; Mullaney, R; Resnick, K; Styler, MJ; Topolsky, D, 1995)
"This high risk of relapse is not observed when the dose of cyclophosphamide is increased to 200 mg/kg."	1.29	Allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: impact of conditioning regimen without total-body irradiation--a report from the Société Française de Greffe de Moelle. ( Bernaudin, F; Blaise, D; Bordigoni, P; Esperou-Bourdeau, H; Gluckman, E; Jouet, JP; Michel, G; Pico, JL; Reiffers, J; Thuret, I, 1994)
"Thirty-eight patients had chronic myelogenous leukemia (17 patients chronic phase, 13 patients accelerated phase, eight patients blast phase), 19 patients had acute leukemia (second complete remission or relapse) and eight patients had myelodysplasia."	1.29	Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen. ( Avalos, B; Bolwell, B; Copelan, E; Crilley, P; Gajewski, J; Klein, J; Sahebi, F; Territo, M, 1996)
"No other relapses have been seen, with one second remission patient remaining leukaemia-free at 24 months, and six first remission patients in continuing remission 11 to 23 (median 20) months post transplant."	1.28	Autologous bone marrow transplantation for acute myeloid leukaemia in remission: a preliminary report. ( Bradstock, KF; Castaldi, PA; Hughes, WG; Kabral, A; Koutts, J; Lee, CH; Posen, J; Robertson, TI, 1990)
"Ninety-nine patients with acute nonlymphocytic leukemia (ANLL) received HLA-identical bone marrow transplants (BMTs) from sibling donors after preparation with high doses of busulfan and cyclophosphamide."	1.28	Allogeneic bone marrow transplantation after high-dose busulfan and cyclophosphamide in patients with acute nonlymphocytic leukemia. ( Ambinder, RF; Beschorner, WB; Braine, HG; Burns, WH; Geller, RB; Piantadosi, S; Saral, R; Vogelsang, GB; Wingard, JR; Zahurak, M, 1989)

Research

Studies (248)

Authors

Clinical Trials (29)

Trial Overview

Trial Outcomes

Percentage of Participants With Chronic Graft-Versus-Host Disease (GVHD)

Timeframe	Studies, this research(%)	All Research%
pre-1990	5 (2.02)	18.7374
1990's	49 (19.76)	18.2507
2000's	64 (25.81)	29.6817
2010's	94 (37.90)	24.3611
2020's	36 (14.52)	2.80

Authors	Studies
Shimoni, A	5
Robin, M	2
Iacobelli, S	1
Beelen, D	2
Mufti, GJ	1
Ciceri, F	5
Bethge, W	4
Volin, L	4
Blaise, D	8
Ganser, A	2
Luft, T	1
Chevallier, P	5
Schwerdtfeger, R	5
Koster, L	1
de Witte, T	1
Kröger, N	19
Nagler, A	15
Yakoub-Agha, I	7
O'Hagan Henderson, S	1
Frietsch, JJ	1
Hilgendorf, I	5
Hochhaus, A	1
Köhne, CH	1
Casper, J	8
Versluijs, AB	1
de Koning, CCH	1
Lankester, AC	1
Nierkens, S	1
Kollen, WJ	1
Bresters, D	1
Lindemans, CA	1
Boelens, JJ	2
Bierings, M	2
Swoboda, R	5
Labopin, M	12
Giebel, S	8
Angelucci, E	2
Arat, M	5
Aljurf, M	2
Sica, S	1
Pavlu, J	3
Socié, G	10
Bernasconi, P	2
Rigacci, L	1
Tischer, J	1
Risitano, A	1
Rovira, M	1
Saccardi, R	1
Pioltelli, P	1
Van Gorkom, G	1
Vitek, A	1
Savani, BN	2
Spyridonidis, A	7
Peric, Z	2
Mohty, M	13
Seydoux, C	1
Battegay, R	1
Halter, J	2
Heim, D	1
Rentsch, KM	1
Passweg, JR	1
Medinger, M	1
Bonifazi, F	3
Pavoni, C	2
Peccatori, J	2
Giglio, F	1
Arpinati, M	1
Busca, A	1
Grassi, A	1
Iori, AP	2
Patriarca, F	2
Brunello, L	1
Di Grazia, C	1
Carella, AM	2
Cilloni, D	1
Picardi, A	2
Proia, A	1
Santarone, S	1
Sorasio, R	1
Carluccio, P	1
Chiusolo, P	1
Cupri, A	1
Luppi, M	1
Nozzoli, C	1
Baronciani, D	2
Casini, M	1
Grillo, G	2
Musso, M	1
Onida, F	1
Palazzo, G	1
Parma, M	1
Tringali, S	1
Vacca, A	1
Vallisa, D	1
Sacchi, N	1
Oldani, E	1
Masciulli, A	2
Gheorghiu, A	1
Girmenia, C	1
Martino, M	2
Bruno, B	6
Rambaldi, A	5
Alatrash, G	2
Saberian, C	1
Bassett, R	2
Thall, PF	2
Ledesma, C	1
Lu, Y	2
Daher, M	1
Valdez, BC	2
Kawedia, J	1
Popat, U	5
Mehta, R	1
Oran, B	3
Nieto, Y	5
Olson, A	1
Anderlini, P	5
Marin, D	1
Hosing, C	5
Alousi, AM	2
Shpall, EJ	5
Rondon, G	6
Chen, J	4
Qazilbash, M	4
Champlin, RE	4
Kebriaei, P	5
Devillier, R	2
Galimard, JE	1
Raiola, AM	1
Castagna, L	3
Chalandon, Y	1
Stölzel, F	1
Bug, G	2
Vrhovac, R	1
Charbonnier, A	1
Olivieri, A	1
Bay, JO	3
Arroyo, H	1
Avenoso, D	2
Neubauer, A	3
Nguyen, S	2
Forcade, E	2
Brissot, E	2
Savani, B	6
Meur, GL	1
Plesa, A	1
Larcher, MV	1
Fossard, G	1
Barraco, F	1
Loron, S	1
Balsat, M	1
Ducastelle-Leprêtre, S	1
Gilis, L	1
Thomas, X	1
Ghesquières, H	2
Tigaud, I	1
Hayette, S	1
Huet, S	1
Sujobert, P	1
Renault, M	1
Thérèse, RM	1
Michallet, M	3
Labussière-Wallet, H	2
Heiblig, M	1
Yi, ES	1
Kim, SK	1
Ju, HY	1
Lee, JW	3
Cho, B	1
Kim, BK	2
Kang, HJ	1
Baek, HJ	1
Kook, H	1
Yang, EJ	1
Lim, YT	1
Ahn, WK	1
Hahn, SM	1
Park, SK	2
Yoo, ES	1
Yoo, KH	1
Klyuchnikov, E	1
Langebrake, C	1
Badbaran, A	1
Dadkhah, A	1
Massoud, R	1
Freiberger, P	1
Ayuk, F	3
Janson, D	1
Wolschke, C	3
Bacher, U	1
Connor, MP	1
Loren, AW	1
Hexner, EO	1
Martin, ME	1
Gill, SI	1
Luger, SM	1
Mangan, JK	1
Perl, AE	1
McCurdy, SR	1
Pratz, KW	1
Timlin, C	1
Freyer, CW	1
Carulli, A	1
Catania, C	1
Smith, J	1
Hollander, L	1
Zebrowski, AM	1
Stadtmauer, EA	1
Porter, DL	2
Frey, NV	1
Luo, C	1
Wu, G	1
Huang, X	1
Ding, Y	1
Huang, Y	1
Song, Q	1
Hou, Y	1
Li, X	1
Xu, S	1
Schroeder, T	4
Hamladji, RM	4
Potter, V	5
Berceanu, A	3
Ozdogu, H	4
Sanz, J	5
Maertens, J	1
Bourhis, JH	2
Salmenniemi, U	1
Poiré, X	1
Cornelissen, JJ	1
Xuan, L	2
Dai, M	1
Jiang, E	2
Wang, Y	1
Huang, F	2
Fan, Z	2
Xu, N	2
Nie, D	2
Liang, X	2
Chen, H	2
Ye, J	1
Shi, P	1
Liu, H	4
Jin, H	2
Lin, R	2
Yan, C	1
Zhang, Y	2
Sun, J	2
Han, M	2
Liu, Q	2
Rehman, MEU	1
Chattaraj, A	1
Mahboob, A	1
Ijaz, Z	1
Franco, D	1
Farhan, M	1
Dharma, K	1
Mumtaz, H	1
Saeed, S	1
Basit, J	1
Aslam, MM	1
Iftikhar, A	1
Faraz, F	1
Anwer, F	1
Shibata, S	1
Arai, Y	1
Kondo, T	2
Mizuno, S	2
Harada, K	1
Miyakoshi, S	2
Uchida, N	3
Maruyama, Y	2
Eto, T	2
Katsuoka, Y	1
Matsue, K	1
Nishiwaki, K	1
Takada, S	1
Doki, N	1
Itoh, M	1
Nagafuji, K	2
Kawakita, T	2
Tanaka, J	1
Fukuda, T	2
Atsuta, Y	5
Yanada, M	2
Niittyvuopio, R	1
Stelljes, M	5
Reinhardt, HC	1
Kaare, A	1
Schäfer-Eckart, K	2
Verbeek, M	1
Mielke, S	1
Carlson, K	1
Bazarbachi, A	1
Hirschbühl, K	1
Polge, E	1
Bonnet, S	1
Schmid, C	2
Ling, Y	1
Guo, Z	1
Xu, X	2
Yu, S	1
Zhang, H	2
Wu, M	1
Liu, C	1
Ou, R	1
Liu, X	2
Qu, H	1
Zhai, X	1
Zhao, Y	1
Cao, J	1
Wang, T	2
Chen, D	1
Li, S	1
Ye, P	1
Zheng, ZZ	1
Pei, R	1
Mariano, B	1
Hamerschlak, N	1
Vera, M	1
Belén, C	1
Andrés, GP	1
Gonzalo, F	1
José, RJ	1
Adriana, V	1
Alberto, GC	1
Georgina, B	1
Sebastián, Y	1
Juliana, MR	1
Martin, S	1
Sol, J	1
Amalia, C	1
Cinthya, CDS	1
Morgani, R	1
Leandro, R	1
Jorge, A	1
Gustavo, K	1
Lisa, BA	1
Mehra, V	1
Slonim, LB	1
de Farias, M	1
Alshehri, H	1
Bouziana, S	1
Krishnamurthy, P	1
Kulasekararaj, A	1
Dazzi, F	1
Wood, H	1
Kenyon, M	1
Leung, YT	1
Anteh, S	1
Shah, MN	1
Hannah, G	1
Serpenti, F	1
Gameil, A	1
Bourlon, C	1
Dragoi, OD	1
Pagliuca, A	1
Joseph, J	1
Srour, SA	1
Milton, DR	1
Ramdial, JL	1
Saini, NY	1
Olson, AL	1
Bashir, Q	4
Qazilbash, MH	1
Popat, UR	1
Zheng, X	2
Gao, H	1
Lu, N	1
Wang, M	2
Zheng, Y	1
Shen, B	1
Cao, Y	1
Chen, X	2
Zhai, W	1
Wei, J	1
Yang, D	1
Zhang, R	2
Pang, A	1
Feng, S	1
Jentzsch, M	1
Döhring, C	1
Linke, R	1
Hille, A	1
Grimm, J	1
Pönisch, W	1
Vucinic, V	1
Franke, GN	1
Behre, G	2
Niederwieser, D	3
Schwind, S	1
Terakura, S	2
Onizuka, M	1
Fukumoto, M	2
Kuwatsuka, Y	2
Kohno, A	2
Ozawa, Y	2
Miyamura, K	2
Inagaki, Y	1
Sawa, M	2
Suzuki, R	2
Naoe, T	2
Morishita, Y	2
Murata, M	2
Ahmed, S	3
Ghosh, N	2
Ahn, KW	2
Khanal, M	2
Litovich, C	2
Mussetti, A	1
Chhabra, S	1
Cairo, M	1
Mei, M	1
William, B	1
Nathan, S	1
Bejanyan, N	1
Olsson, RF	1
Dahi, PB	1
van der Poel, M	1
Steinberg, A	1
Kanakry, J	1
Cerny, J	1
Farooq, U	1
Seo, S	1
Kharfan-Dabaja, MA	7
Sureda, A	2
Fenske, TS	1
Hamadani, M	4
Lee, SS	1
Jung, SH	1
Do, YR	1
Kim, DS	1
Lee, JH	7
Park, HS	2
Moon, JH	2
Yi, JH	1
Park, Y	1
Koh, Y	1
Yhim, HY	1
Choi, Y	2
Mun, YC	1
Lee, WS	1
Lee, S	3
Yang, DH	2
Bacher, VU	1
Bredeson, C	1
Epperla, N	1
Farhadfar, N	1
Freytes, CO	1
Ganguly, S	1
Haverkos, B	1
Inwards, D	1
Kamble, RT	1
Lazarus, HM	4
Lekakis, L	1
Murthy, HS	1
Nishihori, T	3
Ramakrishnan, P	1
Rizzieri, DA	2
Yared, JA	1
Abdelaty, MM	1
Gawaly, A	1
Fathy, GM	1
Kabbash, I	1
Taha, A	1
McCune, JS	5
McKiernan, JS	1
van Maarseveen, E	1
Huitema, ADR	1
Randolph, TW	1
Deeg, HJ	11
Nakamura, R	1
Baker, KS	1
Craddock, C	2
Jackson, A	1
Loke, J	1
Siddique, S	1
Hodgkinson, A	1
Mason, J	1
Andrew, G	1
Nagra, S	1
Malladi, R	1
Peniket, A	1
Gilleece, M	1
Salim, R	1
Tholouli, E	1
Crawley, C	1
Wheatley, K	1
Protheroe, R	1
Vyas, P	1
Hunter, A	1
Parker, A	1
Wilson, K	1
Byrne, J	1
Dillon, R	1
Khan, N	1
McCarthy, N	1
Freeman, SD	1
Edahiro, T	1
Kawase, T	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Reduced Intensity Conditioning With Fludarabine and Busulfan Versus Fludarabine and Melphalan Before Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Randomised, Single-Center, Phase III Study[NCT05674539]	Phase 3	200 participants (Anticipated)	Interventional	2022-12-28	Recruiting
Allogeneic Hematopoietic Cell Transplant for Hematological Cancers and Myelodysplastic Syndromes in HIV-Infected Individuals (BMT CTN #0903)[NCT01410344]	Phase 2	20 participants (Actual)	Interventional	2011-09-30	Completed
A Randomized, Multi-Center, Phase III Study of Allogeneic Stem Cell Transplantation Comparing Regimen Intensity in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia (BMT CTN #0901)[NCT01339910]	Phase 3	272 participants (Actual)	Interventional	2011-06-30	Terminated (stopped due to Accrual terminated as recommended by the data and safety monitoring board.)
Phase I Trial of Haploidentical Natural Killer (NK) Cells in Combination With Pemetrexed in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)[NCT03366064]	Phase 1	5 participants (Actual)	Interventional	2017-11-09	Completed
Allogeneic HCT From Donor-sources of Matched-sibling, Matched-unrelated, or Haploidentical-family Donors Using Uniform Conditioning Regimen of Busulfan, Fludarabine, and Antithymocyte Globulin for AML in Remission - an Observational Study[NCT03337568]		110 participants (Anticipated)	Observational	2017-04-01	Recruiting
Busulfan Plus Cyclophosphamide vs Total Body Irradiation Plus Cyclophosphamide Conditioning Regimen for Standard-risk Acute Lymphocytic Leukemia Undergoing HLA-matched Allogeneic Hematopoietic Stem Cell Transplantation[NCT02670252]	Phase 3	550 participants (Actual)	Interventional	2016-01-31	Completed
A Phase II Open-label, Multicenter, Non Randomized Study Evaluating the Efficacy and the Safety of Clofarabine in Combination With IV Busulfan and Thymoglobulin (CBT) as a Reduced Intensity Conditioning Regimen Prior to Allogeneic Stem Cell Transplantatio[NCT00863148]	Phase 2	30 participants (Actual)	Interventional	2009-10-31	Completed
The Use of Granulocyte Transfusions After Umbilical Cord Blood Transplant for Leukaemia: A Prospective, Non-randomised, Single-centre Study to Evaluate Safety and Immune Reconstitution[NCT05425043]		20 participants (Anticipated)	Interventional	2021-09-14	Recruiting
Phase I/II Study Evaluating Safety and Efficacy of Autologous Hematopoietic Stem and Progenitor Cells Genetically Modified With IDUA Lentiviral Vector Encoding for the Human α-L-iduronidase Gene for the Treatment of Patients Affected by Mucopolysaccharido[NCT03488394]	Phase 1/Phase 2	8 participants (Actual)	Interventional	2018-05-11	Active, not recruiting
Safety and Efficacy Study of Busulfan/FLAG Conditioning Regimen in Patients With Relapsed/Refractory Acute Leukemia Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation[NCT02784561]	Phase 4	80 participants (Anticipated)	Interventional	2016-07-31	Not yet recruiting
Sequential Intensive Chemotherapy Followed by Allogeneic Stem Cell Transplantation With Reduce-intensity Conditioning for Refractory and Relapse Acute Myeloid Leukemia in Adult Patients[NCT01496547]	Phase 2	47 participants (Actual)	Interventional	2011-01-31	Completed
Vorinostat (SAHA) Combined With High-Dose Gemcitabine, Busulfan, and Melphalan With Autologous Hematopoietic Cell Support for Patients With Relapsed or Refractory Lymphoid Malignancies[NCT01421173]	Phase 1	78 participants (Actual)	Interventional	2011-08-31	Completed
Allogeneic Hematopoietic Cell Transplantation for Patients With Hematologic Disorders Who Are Undergoing Dose-Adjusted Treatment With A Maximally Intensive Busulfex-Based Therapeutic Regimen[NCT00448357]	Phase 1/Phase 2	54 participants (Actual)	Interventional	2005-10-31	Completed
A Clinical Study of Low-dose Total Body Irradiation and Fludarabine/Busulfan/Melphalan as a Conditioning Regimen for Secondary Umbilical Cord Blood Transplantation in Patients With Hematological Malignancies Who Relapsed After Allo-HSCT[NCT06125483]		38 participants (Anticipated)	Interventional	2023-11-01	Recruiting
PRO#1278: A Phase III Study of Fludarabine and Busulfan Versus Fludarabine, Busulfan and Low Dose Total Body Irradiation in Patients Receiving an Allogeneic Hematopoietic Stem Cell Transplant[NCT01366612]	Phase 3	53 participants (Actual)	Interventional	2010-06-16	Terminated (stopped due to Lack of Accrual)
Allogeneic Stem Cell Transplantation After Dose-reduced Intensity Conditioning Regimen for Patients With Myelofibrosis With Myeloid Metaplasia (MMM): A Phase II-study[NCT00599547]	Phase 2	106 participants (Actual)	Interventional	2002-11-30	Completed
A Phase II Multicentre, Randomized, Controlled Open-label Study on the Use of Anti-thymocyte Globulin and Rituximab for Immunomodulation of Graft-versus-host Disease in Allogeneic Matched Transplants for Non Malignancies[NCT01810926]	Phase 2	130 participants (Anticipated)	Interventional	2011-09-30	Recruiting
Clinical Phase II Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome (MDS)[NCT01062490]	Phase 2	45 participants (Actual)	Interventional	2004-11-30	Completed
Busulfan Dose Escalation Study Based on AUC in the Setting of Busulfan/Fludarabine Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation (HCT)[NCT00361140]	Phase 4	72 participants (Actual)	Interventional	2005-08-31	Completed
Addition of Gemcitabine to the Standard Reduced Busulfan and Cyclophosphamide (BUCY2) Pre Allogeneic Hematopoietic Stem Cell Transplantation Conditioning for Acute Lymphoblastic Leukemia[NCT03339700]	Phase 2	15 participants (Anticipated)	Interventional	2018-09-15	Recruiting
Transplantation of Ex-vivo Expanded Human Cord Blood Hematopoietic Stem Cells Expanded: Evaluation of Hematopoietic and Immunologic Reconstitution After a Reduced-intensity Conditioning Regimen[NCT01034449]	Phase 2	16 participants (Actual)	Interventional	2010-02-28	Completed
Intrabone Infusion of Cord Blood Hemopoietic Stem Cells in Adult Patients With High Risk Haematological Malignancies.[NCT00886522]	Phase 2	23 participants (Actual)	Interventional	2009-04-30	Completed
Allogeneic Stem Cell Transplantation With Alternative Donor in Treatment of Hematologic Malignancy[NCT02487069]		876 participants (Actual)	Interventional	2015-06-30	Completed
Phase II Trial of Fludarabine Combined With Intravenous Treosulfan and Allogeneic Hematopoietic Stem-cell Transplantation in Patients With Chemo-refractory or Previously Untreated Acute Myeloid Leukemia and Myelodysplastic Syndrome.[NCT00491634]	Phase 2	24 participants (Anticipated)	Interventional	2007-06-30	Completed
Single Arm, Open Label, Phase I Study for Dose and Schedule Finding of Decitabine in Patients With Higher-risk MDS and MDS/AML Receiving Allogeneic Stem Cell Transplantation[NCT01277484]	Phase 1	19 participants (Actual)	Interventional	2011-01-31	Active, not recruiting
Randomised Multicentre Phase IV Study to Compare Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec® in Combination With Interferon Alpha at Low Doses in the Treatment of Newly-Diagnosed Chronic-Phase Chronic Myeloid Leukaemia[NCT00390897]	Phase 4	360 participants	Interventional	2003-07-31	Completed
PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia[NCT00494897]	Phase 4	374 participants (Actual)	Interventional	1996-06-30	Completed
Single Arm Phase II Study of Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia (ALL) in Older Patients Using Fludarabine and Total Body Irradiation (FluTBI) Regimen[NCT01991457]	Phase 2	19 participants (Actual)	Interventional	2013-08-27	Completed
Non-Myeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Chronic Phase CML[NCT00001144]	Phase 2	50 participants	Interventional	1999-10-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Chronic GVHD is classified per 2005 NIH Consensus Criteria (Filipovich et al. 2005) into categories of severity: none, mild, moderate, and severe. Occurrence of chronic GVHD is defined as the occurrence of mild, moderate, or severe chronic GVHD per this classification. (NCT01410344)
Timeframe: 1 Year Post-transplant

Percentage of Participants With Relapse/Progression

Intervention	percentage of participants (Number)
Allogeneic Transplant	17.6

Relapse/Progression is defined as relapse or progression of the primary malignancy. (NCT01410344)
Timeframe: 1 Year Post-transplant

Percentage of Participants Recovering Hematologic Function

Intervention	percentage of participants (Number)
Allogeneic Transplant	29.4

Recovery of hematologic function is described by the time to neutrophil and platelet recovery. Time to neutrophil recovery will be the first of three consecutive days of > 500 neutrophils/μL following the expected nadir. Time to platelet engraftment will be described by the date when platelet count is > 20,000/μL for the first of three consecutive labs with no platelet transfusions 7 days prior. (NCT01410344)
Timeframe: Days 28 and 100 Post-transplant

Percentage of Participants With Acute Graft-Versus-Host Disease (GVHD)

Intervention	percentage of participants (Number)
	Day 28 Neutrophil Recovery	Day 100 Platelet Recovery
Allogeneic Transplant	100.0	94.1

"Acute GVHD is graded according to the scoring system proposed by Przepiorka et al.1995:~Skin stage:~0: No rash~Rash <25% of body surface area~Rash on 25-50% of body surface area~Rash on > 50% of body surface area~Generalized erythroderma with bullous formation~Liver stage (based on bilirubin level)*:~0: <2 mg/dL 1.2-3 mg/dL 2.3.01-6 mg/dL 3.6.01-15.0 mg/dL 4.>15 mg/dL~GI stage*:~0: No diarrhea or diarrhea <500 mL/day~Diarrhea 500-999 mL/day or persistent nausea with histologic evidence of GVHD~Diarrhea 1000-1499 mL/day~Diarrhea >1500 mL/day~Severe abdominal pain with or without ileus * If multiple etiologies are listed for liver or GI, the organ system is downstaged by 1.~GVHD grade:~0: All organ stages 0 or GVHD not listed as an etiology I: Skin stage 1-2 and liver and GI stage 0 II: Skin stage 3 or liver or GI stage 1 III: Liver stage 2-3 or GI stage 2-4 IV: Skin or liver stage 4" (NCT01410344)
Timeframe: Day 100 Post-transplant

Percentage of Participants With Non-Relapse Mortality

Intervention	percentage of participants (Number)
	Grade II-IV Acute GVHD	Grade III-IV Acute GVHD
Allogeneic Transplant	41.2	11.8

The events for non-relapse mortality are death due to any cause other than relapse of the underlying malignancy. (NCT01410344)
Timeframe: Day 100, 1 Year, and 2 Years Post-transplant

Percentage of Participants With Overall Survival

Intervention	percentage of participants (Number)
	Day 100	1 Year	2 Years
Allogeneic Transplant	0.0	11.8	18.3

Overall survival is defined as the time from transplant to death from any cause. (NCT01410344)
Timeframe: Six months, 1 Year, and 2 Years Post-transplant

Chimerism

Intervention	percentage of participants (Number)
	6 Months	1 Year	2 Years
Allogeneic Transplant	82.4	58.8	50.2

Donor T-cell and myeloid chimerism will be described separately by conditioning regimen intensity (myeloablative or reduced intensity) according to proportions with mixed chimerism (5-95% donor cells out of all), full chimerism (>95% donor cells), or graft rejection (<5% donor cells). (NCT01410344)
Timeframe: Week 4, Day 100, and 6 months Post-transplant

Number of Participants With Primary Graft Failure

Intervention	Participants (Count of Participants)
	Week 472365409	Week 472365410	Day 10072365410	Day 10072365409	6 Months72365409	6 Months72365410
	Graft Rejection	No Assay Reported	Full Chimerism	Mixed Chimerism	Dead at Assessment
Reduced Intensity Allogeneic Transplant	4
Myeloablative Allogeneic Transplant	1
Myeloablative Allogeneic Transplant	3
Myeloablative Allogeneic Transplant	4
Reduced Intensity Allogeneic Transplant	5
Myeloablative Allogeneic Transplant	2
Reduced Intensity Allogeneic Transplant	2
Myeloablative Allogeneic Transplant	0
Reduced Intensity Allogeneic Transplant	0

Primary graft failure is defined by lack of neutrophil engraftment. (NCT01339910)
Timeframe: 28 days post-transplant

Number of Participants With Secondary Graft Failure

Intervention	Participants (Count of Participants)
Myeloablative Conditioning Regimen (MAC)	1
Reduced Intensity Conditioning (RIC)	3

Secondary graft failure is defined by initial neutrophil engraftment followed by subsequent decline in neutrophil counts to less than 500x10^6/liter that is unresponsive to growth factor therapy. (NCT01339910)
Timeframe: 18 months post-transplant

Percentage of Participants With Chronic GVHD

Intervention	Participants (Count of Participants)
Myeloablative Conditioning Regimen (MAC)	1
Reduced Intensity Conditioning (RIC)	4

Percentage of Participants With Disease Relapse

Intervention	percentage (Number)
Myeloablative Conditioning Regimen (MAC)	64.0
Reduced Intensity Conditioning (RIC)	47.6

Disease Relapse is defined as relapse of the primary disease. (NCT01339910)
Timeframe: 18 months post-randomization

Percentage of Participants With Overall Survival (OS)

Intervention	percentage (Number)
Myeloablative Conditioning Regimen (MAC)	13.5
Reduced Intensity Conditioning (RIC)	48.3

Overall survival is defined as survival of death from any cause. (NCT01339910)
Timeframe: 18 months post-randomization

Percentage of Participants With Relapse-Free Survival (RFS)

Intervention	percentage (Number)
Myeloablative Conditioning Regimen (MAC)	77.5
Reduced Intensity Conditioning (RIC)	67.7

Relapse-free survival is defined as survival without relapse of the primary disease. (NCT01339910)
Timeframe: 18 months post-randomization

Percentage of Participants With Treatment-related Mortality

Intervention	percentage (Number)
Myeloablative Conditioning Regimen (MAC)	67.8
Reduced Intensity Conditioning (RIC)	47.3

Treatment-related mortality is defined as death without a previous relapse of the primary disease. (NCT01339910)
Timeframe: 18 months post-randomization

Percentage of Participants With Acute Graft Versus Host Disease (GVHD)

Intervention	percentage (Number)
Myeloablative Conditioning Regimen (MAC)	15.8
Reduced Intensity Conditioning (RIC)	4.4

"Acute GVHD is graded according to the scoring system proposed by Przepiorka et al.1995:~Skin stage:~0: No rash~Rash <25% of body surface area~Rash on 25-50% of body surface area~Rash on > 50% of body surface area~Generalized erythroderma with bullous formation~Liver stage (based on bilirubin level)*:~0: <2 mg/dL~2-3 mg/dL~3.01-6 mg/dL~6.01-15.0 mg/dL~>15 mg/dL~GI stage*:~0: No diarrhea or diarrhea <500 mL/day~Diarrhea 500-999 mL/day or persistent nausea with histologic evidence of GVHD~Diarrhea 1000-1499 mL/day~Diarrhea >1500 mL/day~Severe abdominal pain with or without ileus * If multiple etiologies are listed for liver or GI, the organ system is downstaged by 1.~GVHD grade:~0: All organ stages 0 or GVHD not listed as an etiology I: Skin stage 1-2 and liver and GI stage 0 II: Skin stage 3 or liver or GI stage 1 III: Liver stage 2-3 or GI stage 2-4 IV: Skin or liver stage 4" (NCT01339910)
Timeframe: Day 100 post-transplant

Percentage of Participants With Neutrophil and Platelet Engraftment

Intervention	percentage (Number)
	Grade II-IV Acute GVHD	Grade III-IV Acute GVHD
Myeloablative Conditioning Regimen (MAC)	44.7	13.6
Reduced Intensity Conditioning (RIC)	31.6	6.8

Neutrophil engraftment is defined as achieving an absolute neutrophil count greater than 500x10^6/liter for 3 consecutive measurements on different days. The first of the 3 days will be designated the day of neutrophil engraftment. Platelet engraftment is defined as achieving platelet counts greater than 20,000/microliter for consecutive measurements over 7 days without requiring platelet transfusions. The first of the 7 days will be designated the day of platelet engraftment. Subjects must not have had platelet transfusions during the preceding 7 days. (NCT01339910)
Timeframe: Days 28 and 60 post-transplant

Number of Participants With Donor Cell Engraftment

Intervention	percentage (Number)
	Neutrophil Engraftment at Day 28	Platelet Engraftment at Day 60
Myeloablative Conditioning Regimen (MAC)	98.5	95.5
Reduced Intensity Conditioning (RIC)	97.8	96.2

Donor cell engraftment will be assessed by donor-recipient chimerism assays. Full donor chimerism is defined as the presence of at least 95% donor cells as a proportion of the total population in the peripheral blood or bone marrow. Graft rejection is defined as the presence of no more than 5% donor cells as a proportion of the total population. Mixed chimerism is defined as the presence of between 5% and 95% donor cells. Mixed or full donor chimerism will be considered evidence of donor engraftment. (NCT01339910)
Timeframe: Days 28 and 100 and 18 months post-transplant

Capacity of Test Dosing of Busulfan That Would Result in the Desired Area Under the Curve Concentration Exposure of Patients Receiving a Full-dose Busulfan Regimen

Intervention	Participants (Count of Participants)
	Day 2872548419	Day 2872548420	Day 10072548420	Day 10072548419	18 Months72548420	18 Months72548419
	Mixed Chimerism	Full Donor Chimerism	Graft Rejection	Death Prior to Assessment	Unknown (relapsed or missing assay)
Myeloablative Conditioning Regimen (MAC)	86
Reduced Intensity Conditioning (RIC)	80
Myeloablative Conditioning Regimen (MAC)	9
Reduced Intensity Conditioning (RIC)	30
Myeloablative Conditioning Regimen (MAC)	1
Myeloablative Conditioning Regimen (MAC)	0
Reduced Intensity Conditioning (RIC)	0
Myeloablative Conditioning Regimen (MAC)	36
Reduced Intensity Conditioning (RIC)	22
Myeloablative Conditioning Regimen (MAC)	106
Reduced Intensity Conditioning (RIC)	86
Myeloablative Conditioning Regimen (MAC)	12
Myeloablative Conditioning Regimen (MAC)	2
Myeloablative Conditioning Regimen (MAC)	6
Reduced Intensity Conditioning (RIC)	8
Myeloablative Conditioning Regimen (MAC)	71
Reduced Intensity Conditioning (RIC)	66
Myeloablative Conditioning Regimen (MAC)	4
Reduced Intensity Conditioning (RIC)	5
Reduced Intensity Conditioning (RIC)	1
Myeloablative Conditioning Regimen (MAC)	31
Reduced Intensity Conditioning (RIC)	42
Myeloablative Conditioning Regimen (MAC)	25
Reduced Intensity Conditioning (RIC)	19

Test doses of busulfan were administered and plasma levels were measured to determine a targeted AUC dosing estimate. The capacity is reported as the precision with which these test dose goals predicted the actual 90-hour mean AUC levels.Dose targeting precision was estimated by root mean squared error. (NCT00448357)
Timeframe: Day -15 to Day -11

Number of Participants With Dose Limiting Toxicities (DLTs)

Intervention	percentage of error (Number)
Dose Level 1	11.7
Dose Level 2	4.9
Dose Level 3	10.2
Dose Level 4	11.1
Dose Level 5	15.9

Dose limiting toxicity will be defined as any irreversible grade 3 or any grade 4 non-hematologic toxicity that is related to busulfan infusion and not graft vs host disease or late infection after recovery from the initial period of myelosuppression. The maximum tolerated dose (MTD) is defined as the dose with probability of dose limiting toxicity (DLT) of 0.25. The dose of continuous infusion IV busulfan based on blood levels derived from a test dose in conjunction with fludarabine and alemtuzumab plus tacrolimus for GVHD prophylaxis. (NCT00448357)
Timeframe: first 6 weeks or 42 days following stem cell infusion

Overall Survival

Intervention	DLTs (Number)
Dose Level 1	1
Dose Level 2	1
Dose Level 3	1
Dose Level 4	2
Dose Level 5	2

Percentage of participants alive at 3 years post transplant (NCT00448357)
Timeframe: Three years post-transplant

Three-year Relapse-free Survival (RFS) Rate at the Maximum Tolerated Dose Identified During Phase I of the Trial (Target AUC 6912)

Intervention	percentage of participants (Number)
Low Busulfan AUC Tertile (5078)	28
Intermediate Busulfan AUC Tertile (6372)	39
High Busulfan AUC Tertile (7605)	55

Relapse is defined as new or increased sites of disease or positive one marrow after a complete response (CR). The RFS was calculated as the percentage of patients who were alive and without relapse at 3 years (NCT00448357)
Timeframe: Three years post-transplant

Incidence of DNA Chimerism in Patients Between One Month Post Transplant

Intervention	percentage of participants (Number)
Low Busulfan AUC Tertile	22
Intermediate Busulfan AUC Tertile	39
High Busulfan AUC Tertile	43

Deoxyribonucleic acid (DNA) chimerism is a measure identifying the genetic profiles of the transplant recipient and of the donor and then evaluating the extent of mixture in the recipient's blood, bone marrow, or other tissue. (NCT00448357)
Timeframe: 30 days post transplant

Incidence of Graft vs Host Disease in Patients Between One Month and Two Years Post Transplant

Intervention	Participants (Count of Participants)
	Whole blood chimerism-Any	Whole blood chimerism->=95% donor	T Cell chimerism-Any	T Cell chimerism>=95% donor
Experimental: GVHD Prophylaxis	49	47	46	30

"GVHD can be mild, moderate or severe depending on the differences in tissue type between patient and donor. GVHD can be acute or chronic. Its symptoms can include:~Rashes, which include burning and redness, that erupt on the palms or soles and may spread to the trunk and eventually to the entire body~Blistering, causing the exposed skin surface to flake off in severe cases~Nausea, vomiting, abdominal cramps, diarrhea and loss of appetite, which can indicate that the gastrointestinal (digestive) tract is affected~Jaundice, or a yellowing of the skin, which can indicate liver damage~Excessive dryness of the mouth and throat, leading to ulcers~Dryness of the lungs, vagina and other surfaces" (NCT00448357)
Timeframe: 100 days post transplant

To Compare the Relapse Rate at 1 Year of Patients With Myeloid Malignancies Receiving Each Treatment

Non-relapse Mortality

Intervention	Participants (Count of Participants)
	Acute GVHD grade >=II	Acute GVHD grades III and IV	Chronic GVHD; intermediate/severe
High Busulfan AUC Tertile	11	3	2
Intermediate Busulfan AUC Tertile	10	4	6
Low Busulfan AUC Tertile	7	2	4

Intervention	Percent (Number)
Group 1	38.9
Group 2	18.8

The number of participants dead due to causes unrelated to relapse within the first 100 days post transplant. (NCT00361140)
Timeframe: 100 days

Severe Venous Occlusive Disease (VOD)/ Sinusoidal Obstructive Syndrome (SOS)

Intervention	participants (Number)
AUC 6000	3
AUC 7500	4
AUC 9000	2

The number of subjects with severe VOD / SOS; severity staged according to criteria set forth by McDonald G.B., Hinds M.S., Fisher L.D., et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med. 1993;118:255-267. Assessed within the first 100 days post transplant. (NCT00361140)
Timeframe: 100 days

Number of Subjects Disease-free Survival

Intervention	participants (Number)
AUC 6000	0
AUC 7500	1
AUC 9000	2

Percentage of patients without relapse of disease at 2 years (NCT01991457)
Timeframe: 2 years post-transplant

Article	Year
Myeloablative conditioning regimens in adult patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation in complete remission: a systematic review and network meta-analysis. Bone marrow transplantation, 2023, Volume: 58, Issue:2 Topics: Adult; Bayes Theorem; Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Tra	2023
Total Body Irradiation Versus Chemotherapy Conditioning in Pediatric Acute Lymphoblastic Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant: A Systematic Review and Meta-Analysis. Clinical lymphoma, myeloma & leukemia, 2023, Volume: 23, Issue:4 Topics: Adolescent; Adult; Busulfan; Child; Child, Preschool; Graft vs Host Disease; Hematopoietic Stem Cell	2023
Epigenetic modulation and other options to improve outcome of stem cell transplantation in MDS. Hematology. American Society of Hematology. Education Program, 2008 Topics: Busulfan; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Drug Therapy, Combinatio	2008
Bone marrow transplantation in acute nonlymphoblastic leukemia. Seminars in hematology, 1984, Volume: 21, Issue:1 Topics: Acute Disease; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclophosphamide; C	1984
Use of busulfan containing chemotherapy for conditioning patients with leukemia for bone marrow allografting. Bone marrow transplantation, 1993, Volume: 12 Suppl 1 Topics: Actuarial Analysis; Adult; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Cyclophospham	1993
Influence of various conditioning regimens on the outcome of bone marrow transplantation for leukemia. Nouvelle revue francaise d'hematologie, 1991, Volume: 33, Issue:6 Topics: Antineoplastic Agents; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclophosph	1991

Article	Year
Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT. British journal of haematology, 2021, Volume: 195, Issue:3 Topics: Adolescent; Adult; Aged; Allografts; Busulfan; Cyclophosphamide; Disease Progression; Female; Follow	2021
Combination of treosulfan, fludarabine and cytarabine as conditioning in patients with acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms. Journal of cancer research and clinical oncology, 2022, Volume: 148, Issue:10 Topics: Busulfan; Cytarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukem	2022
Clofarabine-fludarabine-busulfan in HCT for pediatric leukemia: an effective, low toxicity, TBI-free conditioning regimen. Blood advances, 2022, 03-22, Volume: 6, Issue:6 Topics: Busulfan; Child; Clofarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans	2022
Total body irradiation plus fludarabine versus thiotepa, busulfan plus fludarabine as a myeloablative conditioning for adults with acute lymphoblastic leukemia treated with haploidentical hematopoietic cell transplantation. A study by the Acute Leukemia W Bone marrow transplantation, 2022, Volume: 57, Issue:3 Topics: Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, M	2022
Impact of busulfan pharmacokinetics on outcome in adult patients receiving an allogeneic hematopoietic cell transplantation. Bone marrow transplantation, 2022, Volume: 57, Issue:6 Topics: Adult; Area Under Curve; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; H	2022
Reduced intensity versus non-myeloablative conditioning regimen for haploidentical transplantation and post-transplantation cyclophosphamide in complete remission acute myeloid leukemia: a study from the ALWP of the EBMT. Bone marrow transplantation, 2022, Volume: 57, Issue:9 Topics: Aged; Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hu	2022
Impact on Outcome of Minimal Residual Disease after Hematopoietic Stem Cell Transplantation with Fludarabine, Amsacrine, and Cytosine Arabinoside-Busulfan Conditioning: A Retrospective Monocentric Study. Transplantation and cellular therapy, 2023, Volume: 29, Issue:1 Topics: Amsacrine; Busulfan; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid,	2023
Allogeneic hematopoietic cell transplantation in patients with juvenile myelomonocytic leukemia in Korea: a report of the Korean Pediatric Hematology-Oncology Group. Bone marrow transplantation, 2023, Volume: 58, Issue:1 Topics: Busulfan; Child; Graft vs Host Disease; Hematology; Hematopoietic Stem Cell Transplantation; Humans;	2023
Individualized busulfan dosing improves outcomes compared to fixed-dose administration in pre-transplant minimal residual disease-positive acute myeloid leukemia patients with intermediate-risk undergoing allogeneic stem cell transplantation in CR. European journal of haematology, 2023, Volume: 110, Issue:2 Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid,	2023
Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid Malignancies. Transplantation and cellular therapy, 2023, Volume: 29, Issue:2 Topics: Adult; Aged; Busulfan; Clofarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation;	2023
Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study on behalf of the Acute Leukemia Working Par Bone marrow transplantation, 2023, Volume: 58, Issue:3 Topics: Acute Disease; Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Huma	2023
Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study on behalf of the Acute Leukemia Working Par Bone marrow transplantation, 2023, Volume: 58, Issue:3 Topics: Acute Disease; Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Huma	2023
Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study on behalf of the Acute Leukemia Working Par Bone marrow transplantation, 2023, Volume: 58, Issue:3 Topics: Acute Disease; Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Huma	2023
Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study on behalf of the Acute Leukemia Working Par Bone marrow transplantation, 2023, Volume: 58, Issue:3 Topics: Acute Disease; Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Huma	2023
Fludarabine versus cyclophospamide in combination with myeloablative total body irradiation as conditioning for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study from the Acute Leukemia Working Party American journal of hematology, 2023, Volume: 98, Issue:4 Topics: Acute Disease; Adult; Bone Marrow; Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematopoietic	2023
Advantages of Higher Busulfan Dose Intensity in Fludarabine-Combined Conditioning for Patients with Acute Myeloid Leukemia Undergoing Cord Blood Transplantation. Transplantation and cellular therapy, 2023, Volume: 29, Issue:5 Topics: Busulfan; Cohort Studies; Cord Blood Stem Cell Transplantation; Hematopoietic Stem Cell Transplantat	2023
Fludarabine/TBI 8 Gy versus fludarabine/treosulfan conditioning in patients with AML in first complete remission: a study from the Acute Leukemia Working Party of the EBMT. Bone marrow transplantation, 2023, Volume: 58, Issue:6 Topics: Acute Disease; Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Huma	2023
Total body irradiation versus busulfan based intermediate intensity conditioning for stem cell transplantation in ALL patients >45 years-a registry-based study by the Acute Leukemia Working Party of the EBMT. Bone marrow transplantation, 2023, Volume: 58, Issue:8 Topics: Acute Disease; Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Human	2023
Intensified conditioning regimen with fludarabine combined with post-transplantation cyclophosphamide for haploidentical allogeneic hematopoietic stem cell transplantation in children with high-risk acute leukemia. Hematology (Amsterdam, Netherlands), 2023, Volume: 28, Issue:1 Topics: Acute Disease; Adult; Antilymphocyte Serum; Busulfan; Child; Cyclophosphamide; Cytarabine; Graft vs	2023
Donor Age Influences Graft-Versus-Host Disease Relapse-Free Survival after Allogeneic Stem Cell Transplant in Elderly Patients in Two Countries from Latin America. Hematology/oncology and stem cell therapy, 2023, May-23, Volume: 16, Issue:4 Topics: Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Latin Americ	2023
Myeloablative Dose of Busulfan and Fludarabine Combined with In Vivo T Cell Depletion Is Safe and Effective Conditioning for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients. Transplantation and cellular therapy, 2023, Volume: 29, Issue:11 Topics: Busulfan; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Synd	2023
Transplantation Outcomes of Myelofibrosis with Busulfan and Fludarabine Myeloablative Conditioning. Transplantation and cellular therapy, 2023, Volume: 29, Issue:12 Topics: Busulfan; Graft vs Host Disease; Humans; Methotrexate; Primary Myelofibrosis; Recurrence; Tacrolimus	2023
Efficacy of venetoclax combined with decitabine conditioning regimen for allogeneic hematopoietic stem cell transplantation in high-risk and elderly patients with myeloid neoplasms. Annals of hematology, 2023, Volume: 102, Issue:12 Topics: Aged; Busulfan; Decitabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans;	2023
Comparison of non-myeloablative and reduced-intensity allogeneic stem cell transplantation in older patients with myelodysplastic syndromes. American journal of hematology, 2019, Volume: 94, Issue:12 Topics: Age Factors; Aged; Aged, 80 and over; Busulfan; Comorbidity; Graft vs Host Disease; Humans; Immunosu	2019
Impact of type of reduced-intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma. British journal of haematology, 2020, Volume: 190, Issue:4 Topics: Adolescent; Adult; Aged; Allografts; Busulfan; Cause of Death; Comorbidity; Cyclophosphamide; Female	2020
Reduced-Intensity Conditioning with Busulfan and Fludarabine for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Lymphoblastic Leukemia. Yonsei medical journal, 2020, Volume: 61, Issue:6 Topics: Acute Disease; Adolescent; Adult; Aged; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem	2020
Association of Reduced-Intensity Conditioning Regimens With Overall Survival Among Patients With Non-Hodgkin Lymphoma Undergoing Allogeneic Transplant. JAMA oncology, 2020, 07-01, Volume: 6, Issue:7 Topics: Allografts; Busulfan; Cohort Studies; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Hum	2020
Irradiation free conditioning regimen is associated with high relapse rate in Egyptian patients with acute lymphoblastic leukemia following allogeneic hematopoietic stem cell transplantation. Journal of the Egyptian National Cancer Institute, 2020, Jun-15, Volume: 32, Issue:1 Topics: Adult; Busulfan; Cyclophosphamide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplant	2020
Prediction of Acute Graft versus Host Disease and Relapse by Endogenous Metabolomic Compounds in Patients Receiving Personalized Busulfan-Based Conditioning. Journal of proteome research, 2021, 01-01, Volume: 20, Issue:1 Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Metabolomics; Prog	2021
Allogeneic hematopoietic cell transplantation using fludarabine plus myeloablative busulfan and melphalan confers promising survival in high-risk hematopoietic neoplasms: a single-center retrospective analysis. Hematology (Amsterdam, Netherlands), 2021, Volume: 26, Issue:1 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality	2021
Reduced-toxicity conditioning regimen with busulfan, fludarabine, rATG, and 400 cGy TBI in pediatric patients undergoing hematopoietic stem cell transplant for high-risk hematologic malignancies. Pediatric blood & cancer, 2021, Volume: 68, Issue:8 Topics: Antilymphocyte Serum; Busulfan; Child; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Pr	2021
Comparison of fludarabine, a myeloablative dose of busulfan, and melphalan vs conventional myeloablative conditioning regimen in patients with relapse and refractory acute myeloid leukemia in non-remission status. Bone marrow transplantation, 2021, Volume: 56, Issue:9 Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid,	2021
Prognostic Analysis of Absolute Lymphocyte and Monocyte Counts after Autologous Stem Cell Transplantation in Children, Adolescents, and Young Adults with Refractory or Relapsed Hodgkin Lymphoma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2017, Volume: 23, Issue:8 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Autografts; Busulfan; Child; Deox	2017
Missing HLA C group 1 ligand in patients with AML and MDS is associated with reduced risk of relapse and better survival after allogeneic stem cell transplantation with fludarabine and treosulfan reduced toxicity conditioning. American journal of hematology, 2017, Volume: 92, Issue:10 Topics: Adult; Aged; Busulfan; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Genotype; He	2017
Outcome Analysis of Pediatric Patients with Acute Lymphoblastic Leukemia Treated with Total Body Irradiation-Free Allogeneic Hematopoietic Stem Cell Transplantation: Comparison of Patients with and Without Central Nervous System Involvement. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2017, Volume: 23, Issue:12 Topics: Adolescent; Busulfan; Central Nervous System Neoplasms; Child; Child, Preschool; Cross-Sectional Stu	2017
Outcomes of Children with Hemophagocytic Lymphohistiocytosis Given Allogeneic Hematopoietic Stem Cell Transplantation in Italy. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018, Volume: 24, Issue:6 Topics: Adolescent; Busulfan; Child; Child, Preschool; Female; Graft Rejection; Hematopoietic Stem Cell Tran	2018
A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018, Volume: 24, Issue:8 Topics: Adult; Aged; Busulfan; Cohort Studies; Cyclophosphamide; Female; Graft vs Host Disease; Hematologic	2018
Busulfan-based myeloablative conditioning regimens for haploidentical transplantation in high-risk acute leukemias and myelodysplastic syndromes. European journal of haematology, 2018, Volume: 101, Issue:3 Topics: Adolescent; Adult; Aged; Busulfan; Combined Modality Therapy; Female; Graft vs Host Disease; Hematop	2018
Fludarabine, busulfan, and low-dose TBI conditioning versus cyclophosphamide and TBI in allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia. Leukemia & lymphoma, 2019, Volume: 60, Issue:3 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Thera	2019
A Single-Center Experience With Hematopoietic Stem Cell Transplantation for Pediatric Acute Lymphoblastic Leukemia: A Modest Pitch for Non-Total Body Irradiation Conditioning Regimens. Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 2019, Volume: 17, Issue:2 Topics: Adolescent; Age Factors; Busulfan; Child; Child, Preschool; Cyclophosphamide; Disease Progression; D	2019
Early fluctuations in busulfan levels with therapeutic dose monitoring during allogeneic stem cell transplantation: do they matter? Leukemia & lymphoma, 2019, Volume: 60, Issue:8 Topics: Adult; Aged; Busulfan; Drug Monitoring; Female; Graft Survival; Graft vs Host Disease; Hematopoietic	2019
Comparison of total body irradiation plus cyclophosphamide with busulfan plus cyclophosphamide as conditioning regimens in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplant. Leukemia & lymphoma, 2013, Volume: 54, Issue:11 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Cyclophosphamide	2013
Ex vivo T cell-depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:6 Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Trans	2013
Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2013, Volume: 19, Issue:6 Topics: Adult; Aged; Antilymphocyte Serum; Busulfan; Cord Blood Stem Cell Transplantation; Cyclophosphamide;	2013
National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine-busulfan-antithymocyte globulin conditioning regimen. Leukemia & lymphoma, 2014, Volume: 55, Issue:5 Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busul	2014
Pharmacokinetically-targeted BU and fludarabine as conditioning before allogeneic hematopoietic cell transplantation for adults with ALL in first remission. Bone marrow transplantation, 2014, Volume: 49, Issue:1 Topics: Adult; Aged; Busulfan; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Graft vs Hos	2014
Glutathione transferase-A2 S112T polymorphism predicts survival, transplant-related mortality, busulfan and bilirubin blood levels after allogeneic stem cell transplantation. Haematologica, 2014, Volume: 99, Issue:1 Topics: Adolescent; Adult; Bilirubin; Busulfan; Cell Line, Tumor; Cytokines; Female; Genotype; Glutathione T	2014
Impact on long-term OS of conditioning regimen in allogeneic BMT for children with AML in first CR: TBI+CY versus BU+CY: a report from the Société Française de Greffe de Moelle et de Thérapie Cellulaire. Bone marrow transplantation, 2014, Volume: 49, Issue:3 Topics: Adolescent; Body Weight; Busulfan; Child; Child, Preschool; Cyclophosphamide; Female; France; Graft	2014
Busulfan and melphalan as consolidation therapy with autologous peripheral blood stem cell transplantation following Children's Oncology Group (COG) induction platform for high-risk neuroblastoma: early results from a single institution. Pediatric transplantation, 2014, Volume: 18, Issue:2 Topics: Busulfan; Child; Child, Preschool; Consolidation Chemotherapy; Female; Humans; Infusions, Intravenou	2014
Allogeneic hematopoietic SCT for adults AML using i.v. BU in the conditioning regimen: outcomes and risk factors for the occurrence of hepatic sinusoidal obstructive syndrome. Bone marrow transplantation, 2014, Volume: 49, Issue:5 Topics: Administration, Intravenous; Adolescent; Adult; Aged; Busulfan; Databases, Factual; Disease-Free Sur	2014
Lower dose of antithymocyte globulin does not increase graft-versus-host disease in patients undergoing reduced-intensity conditioning allogeneic hematopoietic stem cell transplant. Leukemia & lymphoma, 2015, Volume: 56, Issue:4 Topics: Adult; Aged; Antilymphocyte Serum; Busulfan; Disease-Free Survival; Dose-Response Relationship, Drug	2015
Feasible outcomes of T cell-replete haploidentical stem cell transplantation with reduced-intensity conditioning in patients with myelodysplastic syndrome. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:2 Topics: Acute Disease; Adult; Aged; Antilymphocyte Serum; Busulfan; Chronic Disease; Female; Graft vs Host D	2015
Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma. Clinical lymphoma, myeloma & leukemia, 2015, Volume: 15, Issue:6 Topics: Administration, Intravenous; Adult; Aged; Antineoplastic Agents; Busulfan; Disease-Free Survival; Dr	2015
Clinical comparison of weight- and age-based strategy of dose administration in children receiving intravenous busulfan for hematopoietic stem cell transplantation. Pediatric transplantation, 2015, Volume: 19, Issue:3 Topics: Adolescent; Age Factors; Body Weight; Busulfan; Child; Child, Preschool; Cyclophosphamide; Female; F	2015
Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:6 Topics: Acute Disease; Busulfan; Child; Child, Preschool; Chronic Disease; Cord Blood Stem Cell Transplantat	2015
Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:6 Topics: Acute Disease; Busulfan; Child; Child, Preschool; Chronic Disease; Cord Blood Stem Cell Transplantat	2015
Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:6 Topics: Acute Disease; Busulfan; Child; Child, Preschool; Chronic Disease; Cord Blood Stem Cell Transplantat	2015
Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:6 Topics: Acute Disease; Busulfan; Child; Child, Preschool; Chronic Disease; Cord Blood Stem Cell Transplantat	2015
Clinical Relevance of Apheretic Graft Composition in Patients With Acute Myeloblastic Leukemia Who Received a Busulfan-Fludarabine-Antithymocyte Globulin Conditioning Regimen for Allogeneic Transplant. Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation, 2015, Volume: 13, Issue:5 Topics: Adult; Antigens, CD34; Antilymphocyte Serum; B-Lymphocyte Subsets; Blood Component Removal; Busulfan	2015
[Combination of busulfan with increased-dose of fludarabine as conditioning regimen for MDS and MDS-AML patients with allo-HSCT]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2015, Volume: 36, Issue:6 Topics: Busulfan; Disease-Free Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hum	2015
Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:11 Topics: Adult; Busulfan; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantat	2015
Comparison of Outcomes for Pediatric Patients With Acute Myeloid Leukemia in Remission and Undergoing Allogeneic Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens Based on Either Intravenous Busulfan or Total Body Irradiation: A Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:12 Topics: Adolescent; Busulfan; Child; Child, Preschool; Female; Graft vs Host Disease; Hematopoietic Stem Cel	2015
Impact of Thymoglobulin by Stem Cell Source (Peripheral Blood Stem Cell or Bone Marrow) After Myeloablative Stem Cell Transplantation From HLA 10/10-Matched Unrelated Donors: A Report From the Société Française de Greffe de Moelle et de Thérapie Cellulair Transplantation, 2016, Volume: 100, Issue:8 Topics: Adolescent; Adult; Antilymphocyte Serum; Bone Marrow Transplantation; Busulfan; Chi-Square Distribut	2016
[The curative efficacy of unrelated umbilical cord blood stem cells transplantation in intensified myeloablative conditioned patients with acute lymphoblastic leukemia]. Zhonghua nei ke za zhi, 2016, Volume: 55, Issue:3 Topics: Adolescent; Adult; Busulfan; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Cyclopho	2016
Outcome after Transplantation According to Reduced-Intensity Conditioning Regimen in Patients Undergoing Transplantation for Myelofibrosis. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:7 Topics: Aged; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male	2016
Does anti-thymocyte globulin have a place in busulfan/fludarabine conditioning for matched related donor hematopoietic stem cell transplantation? The Korean journal of internal medicine, 2016, Volume: 31, Issue:4 Topics: Acute Disease; Adult; Antilymphocyte Serum; Busulfan; Chronic Disease; Disease-Free Survival; Drug T	2016
Idarubicin-intensified BUCY2 conditioning regimen improved survival in high-risk acute myeloid, but not lymphocytic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: A retrospective comparative study. Leukemia research, 2016, Volume: 46 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Cyclophosphamide	2016
Fludarabine-Busulfan Reduced-Intensity Conditioning in Comparison with Fludarabine-Melphalan Is Associated with Increased Relapse Risk In Spite of Pharmacokinetic Dosing. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:8 Topics: Adolescent; Adult; Aged; Area Under Curve; Busulfan; Female; Humans; Karnofsky Performance Status; L	2016
Levetiracetam for the prevention of busulfan-induced seizures in pediatric hematopoietic cell transplantation recipients. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2017, Volume: 23, Issue:5 Topics: Adolescent; Anticonvulsants; Busulfan; Child; Child, Preschool; Female; Graft Rejection; Hematopoiet	2017
A Novel Reduced-Toxicity Myeloablative Conditioning Regimen Using Full-Dose Busulfan, Fludarabine, and Melphalan for Single Cord Blood Transplantation Provides Durable Engraftment and Remission in Nonremission Myeloid Malignancies. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:10 Topics: Adult; Aged; Busulfan; Female; Graft Survival; Humans; Leukemia, Myeloid; Male; Melphalan; Middle Ag	2016
Allogeneic Hematopoietic Stem Cell Transplantation after Conditioning Regimens with Fludarabine/melphalan or Fludarabine/busulfan for Patients with Hematological Malignancies: A Single-center Analysis. Internal medicine (Tokyo, Japan), 2016, Volume: 55, Issue:13 Topics: Adult; Antineoplastic Agents; Busulfan; Drug Therapy, Combination; Female; Hematologic Neoplasms; He	2016
A 5-day cytoreductive chemotherapy followed by haplo-identical hsct (FA5-BUCY) as a tumor-ablative regimen improved the survival of patients with advanced hematological malignancies. Oncotarget, 2016, Nov-29, Volume: 7, Issue:48 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Chemotherapy, Adjuvant;	2016
Impact of Conditioning Regimen on Outcomes for Children with Acute Myeloid Leukemia Undergoing Transplantation in First Complete Remission. An Analysis on Behalf of the Pediatric Disease Working Party of the European Group for Blood and Marrow Transplanta Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2017, Volume: 23, Issue:3 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Cyclo	2017
Mortality outcomes after busulfan-containing conditioning treatment and haemopoietic cell transplantation in patients with Gilbert's syndrome: a retrospective cohort study. The Lancet. Haematology, 2016, Volume: 3, Issue:11 Topics: Adult; Bilirubin; Busulfan; Cohort Studies; Cyclophosphamide; Dose-Response Relationship, Drug; Fema	2016
Comparative Effectiveness of Busulfan and Fludarabine versus Fludarabine and 400 cGy Total Body Irradiation Conditioning Regimens for Acute Myeloid Leukemia/Myelodysplastic Syndrome. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2017, Volume: 23, Issue:5 Topics: Adult; Aged; Busulfan; Erythrocyte Transfusion; Female; Graft vs Host Disease; Humans; Leukemia, Mye	2017
Outcomes of children, adolescents, and young adults following allogeneic stem cell transplantation for secondary acute myeloid leukemia and myelodysplastic syndromes-The MD Anderson Cancer Center experience. Pediatric transplantation, 2017, Volume: 21, Issue:3 Topics: Adolescent; Adult; Busulfan; Child; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplan	2017
HLA haploidentical hematopoietic cell transplantation using clofarabine and busulfan for refractory pediatric hematological malignancy. International journal of hematology, 2017, Volume: 105, Issue:5 Topics: Adenine Nucleotides; Arabinonucleosides; Busulfan; Child; Clofarabine; Female; Follow-Up Studies; Ha	2017
Incidence and risk factor of hemorrhagic cystitis after allogeneic transplantation with fludarabine, busulfan, and anti-thymocyte globulin myeloablative conditioning. Transplant infectious disease : an official journal of the Transplantation Society, 2017, Volume: 19, Issue:3 Topics: Antilymphocyte Serum; BK Virus; Busulfan; Case-Control Studies; Cystitis; Disease-Free Survival; Dru	2017
Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2008, Volume: 14, Issue:9 Topics: Acute Disease; Adolescent; Adult; Aged; Antibodies, Monoclonal; Antilymphocyte Serum; Busulfan; Chro	2008
Second myeloablative allogeneic stem cell transplantation (SCT) using cord blood for leukemia relapsed after initial allogeneic SCT. Leukemia research, 2009, Volume: 33, Issue:6 Topics: Adolescent; Adult; Antineoplastic Agents; Busulfan; Cyclophosphamide; Female; Fetal Blood; Humans; M	2009
Autologous transplantation for relapsed non-Hodgkin's lymphoma using intravenous busulfan and cyclophosphamide as conditioning regimen: a single center experience. Bone marrow transplantation, 2009, Volume: 44, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Disease Pro	2009
Superior survival after replacing oral with intravenous busulfan in autologous stem cell transplantation for non-Hodgkin lymphoma with busulfan, cyclophosphamide and etoposide. British journal of haematology, 2010, Volume: 148, Issue:2 Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Age	2010
Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2010, Volume: 16, Issue:6 Topics: Age Factors; Aged; Aging; Blood Donors; Busulfan; Disease-Free Survival; Female; Graft vs Host Disea	2010
The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission. Blood, 2010, Jul-22, Volume: 116, Issue:3 Topics: Adolescent; Adult; Aged; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoies	2010
Long term follow-up of allogeneic stem cell transplantation in patients with myelodysplastic syndromes using busulfan, cytosine arabinoside, and cyclophosphamide. American journal of hematology, 2010, Volume: 85, Issue:8 Topics: Adolescent; Adult; Aged; Busulfan; Cyclophosphamide; Cytarabine; Disease-Free Survival; Female; Foll	2010
Retrospective analysis of treosulfan-based conditioning in comparison with standard conditioning in patients with myelodysplastic syndrome. Bone marrow transplantation, 2011, Volume: 46, Issue:4 Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Busulfan; Comorbidity; Disease-Free Surv	2011
Targeted i.v. BU and fludarabine (t-i.v. BU/Flu) provides effective control of AML in adults with reduced toxicity. Bone marrow transplantation, 2011, Volume: 46, Issue:5 Topics: Adult; Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Injec	2011
Pharmacokinetic targeting of i.v. BU with fludarabine as conditioning before hematopoietic cell transplant: the effect of first-dose area under the concentration time curve on transplant-related outcomes. Bone marrow transplantation, 2011, Volume: 46, Issue:11 Topics: Adult; Aged; Area Under Curve; Busulfan; Disease-Free Survival; Female; Hematopoietic Stem Cell Tran	2011
High-dose busulfan and cyclophosphamide as a conditioning regimen for autologous peripheral blood stem cell transplantation in childhood non-Hodgkin lymphoma patients: a long-term follow-up study. Journal of pediatric hematology/oncology, 2011, Volume: 33, Issue:3 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Cyclo	2011
Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning. Hematological oncology, 2011, Volume: 29, Issue:4 Topics: Adult; Aged; Busulfan; Chimerism; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplanta	2011
Idarubicin-intensified BUCY2 regimens may lower relapse rate and improve survival in patients undergoing allo-SCT for high-risk hematological malignancies: a retrospective analysis. Bone marrow transplantation, 2012, Volume: 47, Issue:2 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Chimerism; Combined Mod	2012
Intermediate intensity conditioning regimen containing FLAMSA, treosulfan, cyclophosphamide, and ATG for allogeneic stem cell transplantation in elderly patients with relapsed or high-risk acute myeloid leukemia. Annals of hematology, 2012, Volume: 91, Issue:1 Topics: Adult; Antilymphocyte Serum; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy	2012
Successful pregnancy after busulfan/cytoxan conditioning regimen for AML. Journal of pediatric hematology/oncology, 2011, Volume: 33, Issue:5 Topics: Adult; Busulfan; Child; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; L	2011
Allogeneic hematopoietic cell transplant for peripheral T-cell non-Hodgkin lymphoma results in long-term disease control. Leukemia & lymphoma, 2011, Volume: 52, Issue:8 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Cyclophosp	2011
Intravenous compared with oral busulfan as preparation for allogeneic hematopoietic progenitor cell transplantation for AML and MDS. Bone marrow transplantation, 2012, Volume: 47, Issue:5 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female;	2012
The increase from 2.5 to 5 mg/kg of rabbit anti-thymocyte-globulin dose in reduced intensity conditioning reduces acute and chronic GVHD for patients with myeloid malignancies undergoing allo-SCT. Bone marrow transplantation, 2012, Volume: 47, Issue:5 Topics: Adolescent; Adult; Aged; Animals; Antilymphocyte Serum; Busulfan; Graft vs Host Disease; Hematopoiet	2012
Comparison of new flu-bu12-tg conditioning with the standard bu-cy myeloablative regimen in patients undergoing allogeneic stem cell transplantation for acute myeloid leukemia. Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia, 2011, Volume: 155, Issue:4 Topics: Adult; Antilymphocyte Serum; Busulfan; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Hos	2011
High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012, Volume: 18, Issue:11 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Deoxycytidine; Dr	2012
Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan-cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission. British journal of haematology, 2002, Volume: 119, Issue:4 Topics: Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplanta	2002
Reduced non-relapse mortality after reduced intensity conditioning in advanced chronic lymphocytic leukemia. Annals of hematology, 2002, Volume: 81 Suppl 2 Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive	2002
Busulfan and cyclophosphamide as a preparative regimen for allogeneic blood and marrow transplantation in patients with non-Hodgkin's lymphoma. Bone marrow transplantation, 2003, Volume: 31, Issue:2 Topics: Adult; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Disease-Free Survival; Female; Follo	2003
Aspirin-responsive painful red, blue, black toe, or finger syndrome in polycythemia vera associated with thrombocythemia. Annals of hematology, 2003, Volume: 82, Issue:3 Topics: Aged; Aspirin; Busulfan; Erythromelalgia; Female; Fingers; Hematocrit; Humans; Male; Middle Aged; Pl	2003
Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. Blood, 2003, Jul-15, Volume: 102, Issue:2 Topics: Acute Disease; Adolescent; Adult; Antilymphocyte Serum; Busulfan; Chronic Disease; Disease Progressi	2003
Impact of graft-versus-host disease in reduced-intensity stem cell transplantation (RIST) for patients with haematological malignancies. British journal of haematology, 2003, Volume: 121, Issue:2 Topics: Acute Disease; Adolescent; Adult; Aged; Busulfan; Chronic Disease; Cladribine; Cyclophosphamide; Dis	2003
[Comparison of two conditioning regimens in treatment of leukemia by allogeneic hematopoietic stem cell transplantation]. Ai zheng = Aizheng = Chinese journal of cancer, 2003, Volume: 22, Issue:6 Topics: Adolescent; Adult; Busulfan; Cyclophosphamide; Disease-Free Survival; Female; Hematopoietic Stem Cel	2003
Reduced-intensity conditioning with busulfan and fludarabine with or without antithymocyte globulin in HLA-identical sibling transplantation--a retrospective analysis. Bone marrow transplantation, 2004, Volume: 33, Issue:5 Topics: Acute Disease; Adult; Aged; Antilymphocyte Serum; Busulfan; Chronic Disease; Combined Modality Thera	2004
[Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma]. Bulletin du cancer, 2004, Volume: 91, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neopla	2004
Morbidity and non-relapse mortality after allogeneic bone marrow transplantation in adult leukemia patients conditioned with busulfan plus cyclophosphamide: a retrospective comparison of oral versus intravenous busulfan. Haematologica, 2005, Volume: 90, Issue:2 Topics: Administration, Oral; Adult; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Female; Humans	2005
Possible role of high-dose busulfan in second reciprocal transplant between brother and sister for resistant acute leukemia. Bone marrow transplantation, 2005, Volume: 35, Issue:7 Topics: Bone Marrow Transplantation; Burkitt Lymphoma; Busulfan; Child; Female; Humans; Male; Recurrence; Si	2005
Comparison of ARF after myeloablative and nonmyeloablative hematopoietic cell transplantation. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2005, Volume: 45, Issue:3 Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Busulfan; Cohort Studies; Comorbidity; Cyclophosphamid	2005
[Allogeneic blood stem cell transplantation in high-risk patients after conditioning with treosulfan and fludarabine]. Deutsche medizinische Wochenschrift (1946), 2005, Sep-23, Volume: 130, Issue:38 Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Busulfan; Disease-Free Survival; Do	2005
Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study. European journal of haematology, 2006, Volume: 76, Issue:1 Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Busulfan; Cohort Studies; Combined Modality Th	2006
Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood, 2006, Apr-15, Volume: 107, Issue:8 Topics: Acute Disease; Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protoco	2006
The outcome of children with acute myeloid leukemia (AML) post-allogeneic stem cell transplantation (SCT) is not improved by the addition of etoposide to the conditioning regimen. Pediatric blood & cancer, 2006, Volume: 47, Issue:7 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Cyclo	2006
Long-term follow-up of allogeneic marrow transplantation for acute myelogenous leukemia after treatment with busulfan and cyclophosphamide. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2006, Volume: 12, Issue:3 Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Female; Follow-Up Studie	2006
Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2006, Volume: 12, Issue:10 Topics: Acute Disease; Adult; Aged; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Female; Graft S	2006
Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation. Annals of hematology, 2007, Volume: 86, Issue:8 Topics: Adolescent; Adult; Aged; Busulfan; Chimerism; Female; Graft Survival; Graft vs Host Disease; Hematol	2007
New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2. Bone marrow transplantation, 2007, Volume: 40, Issue:6 Topics: Adolescent; Adult; Arterial Occlusive Diseases; Busulfan; Cyclophosphamide; Cytomegalovirus Infectio	2007
Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortal Leukemia, 2007, Volume: 21, Issue:10 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Graft vs	2007
Long-term follow-up of busulfan, etoposide, and nimustine hydrochloride (ACNU) or melphalan as conditioning regimens for childhood acute leukemia and lymphoma. International journal of hematology, 2007, Volume: 86, Issue:3 Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; C	2007
Intensive chemotherapy, total body irradiation, and autologous marrow transplantation for chronic granulocytic leukemia-blast phase: report of four additional cases. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1984, Volume: 2, Issue:5 Topics: Adult; Bone Marrow; Bone Marrow Transplantation; Busulfan; Child; Chromosomes, Human, 21-22 and Y; C	1984
Circulating immune complexes in chronic myeloid leukemia patients at various stages of the disease. Leukemia research, 1983, Volume: 7, Issue:6 Topics: Acute Disease; Antigen-Antibody Complex; Busulfan; Complement Activating Enzymes; Complement C1q; Hu	1983
Extramedullary toxicity of a conditioning regimen containing busulphan, cyclophosphamide and etoposide in 84 patients undergoing autologous and allogenic bone marrow transplantation. Bone marrow transplantation, 1995, Volume: 15, Issue:3 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow Transplantati	1995
Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:5 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cispla	1995
Allogeneic bone marrow transplantation following busulfan-cyclophosphamide with or without etoposide conditioning regimen for patients with acute lymphoblastic leukaemia. British journal of haematology, 1993, Volume: 85, Issue:4 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busu	1993
Allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: impact of conditioning regimen without total-body irradiation--a report from the Société Française de Greffe de Moelle. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child; Child,	1994
Autologous bone marrow transplantation for acute myeloid leukemia using busulfan plus etoposide as a preparative regimen. Blood, 1993, Jan-15, Volume: 81, Issue:2 Topics: Actuarial Analysis; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantati	1993
Busulfan-based regimens and allogeneic bone marrow transplantation in patients with myelodysplastic syndromes. Blood, 1993, Apr-15, Volume: 81, Issue:8 Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Chromosome Aberra	1993
Minimal residual disease detected by the PCR in chronic myeloid leukemia. Comparison of cyclophosphamide-total body irradiation and busulphan-cyclophosphamide bone marrow transplantation conditioning. Acta haematologica, 1993, Volume: 89, Issue:2 Topics: Adult; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cyclophosphamide; Female; H	1993
A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia. Acute Leukaemia Working Party of the European Group for Blood a British journal of haematology, 1996, Volume: 93, Issue:3 Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Bone Marrow Transplantati	1996
Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen. Bone marrow transplantation, 1996, Volume: 17, Issue:5 Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols	1996
High-dose busulfan and cyclophosphamide followed by autologous transplantation in patients with advanced breast cancer. Bone marrow transplantation, 1996, Volume: 17, Issue:5 Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Marro	1996
Treatment of relapsing experimental autoimmune encephalomyelitis with largely MHC-matched allogeneic bone marrow transplantation. Transplantation, 1996, Sep-27, Volume: 62, Issue:6 Topics: Animals; Antibodies, Monoclonal; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Disease Mo	1996
Intermediate-dose busulphan before autografting for advanced-phase chronic myeloid leukaemia. British journal of haematology, 1996, Volume: 94, Issue:4 Topics: Adult; Aged; Bone Marrow Transplantation; Busulfan; Female; Graft Survival; Hematopoietic Stem Cell	1996
Detection of occasional and clonal chromosome aberrations in patients with acute non-lymphocytic leukemia after autologous bone marrow transplantation. Bone marrow transplantation, 1996, Volume: 18, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Bu	1996
Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood, 1997, Apr-15, Volume: 89, Issue:8 Topics: Adult; Bone Marrow Transplantation; Busulfan; Cause of Death; Cyclophosphamide; Female; Graft Reject	1997
Rat arterial wall retains myointimal hyperplastic potential long after arterial injury. Circulation, 1997, Aug-19, Volume: 96, Issue:4 Topics: Animals; Busulfan; Carotid Artery Injuries; Carotid Artery, Common; Carotid Stenosis; Hyperplasia; M	1997
[Severe hepatic veno-occlusive disease (VOD) which was successfully treated with supportive therapy, but subsequently developed late-recurrence]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 1998, Volume: 39, Issue:2 Topics: Adult; Bone Marrow Transplantation; Busulfan; Chronic Disease; Cyclophosphamide; Cyclosporine; Graft	1998
Busulfan, cyclophosphamide and total body irradiation as conditioning for allogeneic bone marrow transplantation for acute and chronic myeloid leukemia. Bone marrow transplantation, 1998, Volume: 21, Issue:11 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busu	1998
High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma. Bone marrow transplantation, 1998, Volume: 22, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combin	1998
High incidence of extramedullary relapse of AML after busulfan/cyclophosphamide conditioning and allogeneic stem cell transplantation. Bone marrow transplantation, 1998, Volume: 22, Issue:3 Topics: Adolescent; Adult; Busulfan; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease;	1998
Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study. Bone marrow transplantation, 1999, Volume: 23, Issue:3 Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents; Bone Marrow Purging; Busulfan; Combined Mod	1999
[Severe esophageal stenosis secondary to the administration of chemotherapy in a patient with acute myeloblastic leukemia]. Sangre, 1999, Volume: 44, Issue:3 Topics: Anti-Infective Agents; Anti-Ulcer Agents; Antineoplastic Combined Chemotherapy Protocols; Busulfan;	1999
In vivo expansion of reinfused autologous peripheral blood stem cells after a myeloablative regimen, as an alternative to ex vivo expansion pretransplantation: an intriguing observation in apatient autografted twice. Bone marrow transplantation, 1999, Volume: 24, Issue:10 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Busulfan; Cyclophosphamide; Doxoru	1999
Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:2 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busu	2000
High-dose busulphan alone as cytoreduction before allogeneic or autologous stem cell transplantation for chronic myeloid leukaemia: a single-centre experience. British journal of haematology, 2000, Volume: 108, Issue:4 Topics: Adolescent; Adult; Busulfan; Drug Administration Schedule; Female; Hematopoietic Stem Cell Transplan	2000
Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin. Bone marrow transplantation, 2000, Volume: 26, Issue:2 Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Agents; Busulfan; Disease-Free Survival; Female; G	2000
Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia. Bone marrow transplantation, 2000, Volume: 26, Issue:7 Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; B	2000
The influence of early transplantation, age, GVHD prevention regimen, and other factors on outcome of allogeneic transplantation for CML following BuCy. Bone marrow transplantation, 2000, Volume: 26, Issue:10 Topics: Adolescent; Adult; Age Factors; Aged; Bone Marrow Transplantation; Busulfan; Cause of Death; Cycloph	2000
A pilot study of busulfan, cyclophosphamide and etoposide followed by autologous transplantation for acute myeloid leukemia in remission. Acta haematologica, 2000, Volume: 104, Issue:2-3 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Etopo	2000
Low-intensity conditioning is sufficient to ensure engraftment in matched unrelated bone marrow transplantation. Experimental hematology, 2001, Volume: 29, Issue:3 Topics: Adolescent; Adult; Antilymphocyte Serum; Bone Marrow Transplantation; Busulfan; Cell Count; Child; C	2001
Results of an outpatient-based stem cell allotransplant program using nonmyeloablative conditioning regimens. American journal of hematology, 2001, Volume: 66, Issue:4 Topics: Adolescent; Adult; Ambulatory Care; Busulfan; Child; Cyclophosphamide; Cyclosporine; Female; Follow-	2001
Allogeneic bone marrow transplantation for chronic myeloid leukemia: a retrospective study of busulfan-cytoxan versus total body irradiation-cytoxan as preparative regimen in Koreans. Clinical transplantation, 2001, Volume: 15, Issue:3 Topics: Adult; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Drug Administration Schedule; Female	2001
A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome. Bone marrow transplantation, 2001, Volume: 28, Issue:7 Topics: Adult; Anemia, Refractory, with Excess of Blasts; Antilymphocyte Serum; Bone Marrow; Busulfan; Cell	2001
Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma. Annals of hematology, 2002, Volume: 81, Issue:2 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Combined Modality Thera	2002
Relapse of chronic myeloid leukemia (CML) in lymphoid crisis after allogeneic bone marrow transplantation for CML in chronic phase with busulfan plus cyclophosphamide regimen. Haematologica, 2002, Volume: 87, Issue:6 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow Transplantation; Bu	2002
Treatment of recurrent and refractory pediatric solid tumors with high-dose busulfan and cyclophosphamide followed by autologous bone marrow rescue. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1992, Volume: 10, Issue:12 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow	1992
Second transplants for patients with chronic myeloid leukaemia in relapse after original transplant with T-depleted donor marrow: feasibility of using busulphan alone for re-conditioning. British journal of haematology, 1992, Volume: 80, Issue:1 Topics: Adolescent; Adult; Bone Marrow Cells; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Fe	1992
Marrow transplantation in patients with acute myeloid leukemia. Leukemia, 1992, Volume: 6 Suppl 2 Topics: Acute Disease; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Drug Administration Schedule	1992
Radiation-free preparation for allogeneic bone marrow transplantation in adults with acute lymphoblastic leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1992, Volume: 10, Issue:2 Topics: Actuarial Analysis; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow T	1992
Bone marrow transplantation for patients with myelodysplasia. Pretreatment variables and outcome. Annals of internal medicine, 1990, Apr-15, Volume: 112, Issue:8 Topics: Adolescent; Adult; Age Factors; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Comb	1990
Busulfan/cyclophosphamide plus bone marrow transplantation is not sufficient to eradicate the malignant clone in juvenile chronic myelogenous leukemia. Bone marrow transplantation, 1990, Volume: 5, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Child, Presch	1990
Autologous bone marrow transplantation for acute myeloid leukaemia in remission: a preliminary report. Australian and New Zealand journal of medicine, 1990, Volume: 20, Issue:1 Topics: Adult; Bone Marrow Transplantation; Busulfan; Cryopreservation; Cyclophosphamide; Female; Humans; Le	1990
Allogeneic bone marrow transplantation after high-dose busulfan and cyclophosphamide in patients with acute nonlymphocytic leukemia. Blood, 1989, Volume: 73, Issue:8 Topics: Acute Disease; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Drug Administration Schedule	1989
[Recurrent melena and gastrectomy in a patient with chronic myeloid leukemia]. Harefuah, 1973, Jan-15, Volume: 84, Issue:2 Topics: Busulfan; Duodenal Ulcer; Gastrectomy; Humans; Leukemia, Myeloid; Male; Melena; Recurrence	1973

busulfan and Recrudescence